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Bone diseases range from degenerative osteoporosis to bone cancers and 
metastasized malignancies.  They can be congenital or developed late in life and 
represent a major cause of decreased quality of life and increased mortality.  Large 
molecule drug delivery systems have been in development and are aimed at delivering 
targeted drugs to bone.  They do this by increasing accumulation with targeting ligands to 
attach to bone, with large size increasing accumulation in inflamed and malignant tissue 
and extending circulation half-life due to their reduced clearance by the kidneys.  
Unfortunately, they often have large dispersities, making consistency among batches 
more complicated.  Small molecules, on the other hand, can be replicated predictably for 
each batch but lack in extended circulation time and good accumulation due to their size.   
Micelles have the capability of bridging this gap.  By conjugating a high-affinity bone- 
targeting ligand, aspartic acid octapeptide, to a hydrophobic drug by a degradable linker, 
a monodisperse unimer is formed that can self-assemble into a large molecule micelle. 
 This dissertation describes the development of a bone-targeted micelle and the 
incorporation of two different drugs, doxorubicin and 6-bromoindirubin-3’-oxime 
(6BIO), for the application of treating osteosarcoma and bone fractures, respectively.   
 Four doxorubicin-containing micelles were designed and synthesized.  These 
micelles demonstrated micellar aggregation at low concentrations, increasing the overall 
size of the delivery system.  The micelles also were able to retain their binding to 
  iv 
hydroxyapatite and release unmodified drug for treatment of osteosarcoma. 
 From osteosarcoma, efforts were made to examine the versatility of the micellar 
drug delivery system by applying it to bone fractures.  We adapted the delivery system by 
conjugating it to the GSK3β inhibitor, 6BIO.  The modified micelle retained its micelle-
assembling capabilities and was able to release drug over several days.  Animal studies 
demonstrated the micelles’ high affinity to bone fractures and ability to increase the bone 
density of fractured femurs. 
 We have developed a drug delivery system that can be adapted for multiple 
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 Bone is a complex organ responsible for structure and calcium storage as well as 
being a structure for hematopoiesis to occur.  Adult bone is 50-70% mineral, 20-40% 
organic matrix, 5-10% water, and 1-5% lipids.  Hydroxyapatite (HAp) (Ca10(PO4)6(OH)2) 
is the main mineral component of bone.  The crystallinity of HAp increases with time, 
however, in healthy bone the needle-like crystals never grow much more than 300 Å in 
length [1–3].  These crystals are continuously being broken down and replaced during 
bone turnover.  Initially, monocytes receive several signals directing them to differentiate 
into osteoclasts.  Critical to this process, osteoblasts present receptor activator of nuclear 
factor κB ligand (RANKL) to the receptor activator of nuclear factor κB (RANK) surface 
receptor triggering the TNF receptor associated factor 6 (TRAF6) cascade in monocytes, 
ensuring osteoclast development [4,5].  Mature osteoclasts then perform the catabolic 
process on bone.  The osteoclast creates a sealing zone (Figure 1.1) over resorption sites 
(lacunae) and proceeds to release cathepsin K (Cat K) to degrade the organic matrix and 
HCl to dissolve the HAp.  These mechanisms in combination with reactive oxygen 
species (ROS) produced by tartrate-resistant acid phosphatase (TRAP) degrade the bone 
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preparatory for osteoblasts to lay down organic matrix called osteoid.  The osteoid, 
primarily composed of type I collagen, is then calcified and becomes new bone [6,7].  
 When catabolism or anabolism in bone turnover is altered, the bone may become 
diseased.  Osteoporosis, where catabolism effectively outweighs anabolism, 
predominately affects men and women over 50.  Approximately 44 million people in the 
US suffer from low bone mass, and 10 million people already have osteoporosis.  An 
estimated 61 million will have the disease by 2020 [8].  Complications of this disease 
include debilitating vertebral and hip fractures, costing between in $13.7 billion and 
$20.3 billion in 2005 [9].  Other imbalances in bone turnover include osteosarcoma and 
bone metastasis.  Osteolytic and tumor-creating cancers of the bone both result in 
significant pain and morbidity or patients.  Osteoarthritis, osteomyelitis, infections, and 
fractures all increase the economic toll on health systems worldwide as well as decrease 
quality of life for millions of people each year. 
 Nanomedicine plays an important role in recent advancements in bone 
therapeutics.  Diseases that affect the bone may carry a range of receptor-specific 
targeting opportunities or they may carry none at all.  However, by exploiting the mineral 
portion of the bone, bone diseases can be targeted using molecules such as 
bisphosphonate and acidic oligopeptides.  Nanomedicines can be easily conjugated to 
several ionic targeting ligands, increasing binding avidity to bone.  HAp crystal structures 
or HAp exposure are disease specific, and as such, modification of the targeting ligand 
itself or the density of the ligand may provide specific targeting opportunities.  In 
addition to targeting, nanomedicines create an opportunity to image and synergistically 
combine multiple drugs to treat the diseased portion of the bone (Figure 1.2). 
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 Aspects of this field have been reviewed previously [10-15]. In this chapter we 
discuss the selection of proper targeting agents, polymers, and drugs for application to 
specific bone disease states.  The analysis also includes methods of increasing local drug 
accumulation by modification of the molecular weight and drug-polymer release 
mechanisms.  We will also elaborate on how various bone anabolic agents interact, as 
well as how synergism of chemotherapeutics can be achieved by nanomedicine.  
 
1.2. Targeting 
 Each bone disease state has similarities in that each causes local inflammation 
and/or results in the exposure of HAp to blood.  These two characteristics can be utilized 
in order to deliver high drug loads specifically to diseased tissue.  Inflamed tissue fills 
with exudate as various cytokines dilate vasculature.  Macromolecular therapeutics then 
are able to travel into the tissue due to vascular fenestration and be retained in the tissue 
due to poor lymphatic clearance and any targeting ligands associated with the 
macromolecule.  This enhanced permeability and retention (EPR) has been well 
documented in several publications and is extensively discussed in several reviews [16-
19].  Delivery of therapeutics to bone also depends on the extravasation through vessels 
in or near the bone [20]. Larger molecules, for example albumin and 
polyvinylpyrrolidone (Mw 35 kDa), can extravasate and have been found in bone after 
i.v. administration [21].  In fact, it has been long known that the vasculature in bone is 
fenestrated with pore sizes up to 80 nm [22], which exceeds the hydrodynamic size of 
most circulating nanomedicines.  Exposure of HAp to blood carries its own targeting 
possibilities.  Various tetracyclines, bisphosphonates, acidic oligopeptides, chelating 
compounds, and salivary proteins have all been employed to target bone diseases.  These 
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compounds bind to the inorganic HAp part of bone and have specificity for a certain size 
of HAp crystal.  Therefore, as the crystallinity of newly deposited bone in a tumor is 
different from the crystallinity of HAp exposed during a bone fracture, so targeting 
molecules can be selected for specific disease states.  
 
1.2.1 Tetracycline 
 Tetracycline was introduced as an antibiotic in 1947 [23].  The antibiotic is derived 
from Streptomyces rimosus and inhibits aminoacyl-tRNA from entering into bacterial 
ribosomes, inhibiting protein elongation [24]. Tetracycline affects general bacterial 
metabolism and is prescribed for a wide range of gram-positive and gram-negative 
bacteria.  Soon after its incorporation into medicine, however, tetracycline was found to 
bind strongly to bone.  Its usage was discontinued in pediatric medicine as the high 
affinity to HAp caused children’s teeth to stain yellow [25].  Furthermore, other early 
studies found that tetracycline may inhibit skeletal growth in children [26,27].  Its use as 
an antibiotic in adults and a targeting ligand in bone disease, though, has not persisted. 
 Early studies indicate that tetracycline must be in the correct orientation in order to 
bind HAp.  Oxygens bound to C2, C10, and C12 are among the primary HAp binding 
atoms [28].  As such, modifications around the 5, 6, and 7 carbons can be made with 
minimal effects on binding and biological activity (Figure 1.3).  Other studies have 
shown that bone binding and antimicrobial activity may be retained even with a 
simplified tetracycline molecule.  Neale et al. tried to reduce potential side effects caused 
by tetracycline’s biological activity by minimalizing tetracycline structure so that it 
retains no biological activity yet is still able to bind to HAp.  They found that 3-amino-
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2,6-dihydroxybenzamide retains 50% of the ability to bind to HAp when compared to 
native tetracycline (Figure 1.3). To achieve bone anabolism, the new targeting ligand was 
bound to estradiol via a succinate linker.  Following conjugation, the compound had a 
binding affinity of 105% over tetracycline alone.  As estradiol alone did not bind to HAp, 
the increased affinity may be attributed to the addition of a succinate linker [29].   
 
1.2.2 Bisphosphonates 
 Bisphosphonates (BPs) also bind strongly to HAp and retain much of the binding 
affinity after conjugation to other molecules or carriers.  The first biological activity 
associated with BPs was noticed in 1968 [30].  Later, their effects on bone metabolism 
were discovered and they were prescribed to treat osteoporosis.  BPs are derived from 
pyrophosphate and contain a carbon substitution for pyrophosphate’s central oxygen.  
From the central carbon most BPs have been functionalized with a hydroxyl group and an 
R group by which they are classified (R groups containing nitrogen and those that do not) 
(Figure 1.3).  Non-nitrogen-containing BPs incorporate into AMP, creating a modified 
ATP, which cannot be hydrolyzed.  Buildup of this ATP analog inside osteoclasts leads 
to apoptosis and reduced bone turnover.  Nitrogen-containing BPs (nBP) are much more 
potent.  They inhibit farnesyl pyrophosphate synthase activity, and by so doing, disrupt 
the mevalonic acid pathway.  Without the mevalonic acid pathway, protein prenylation is 
inhibited and osteoclasts lose their functionality or apoptose [31].  This inhibition may 
not completely arrest bone turnover, as mevalonic acid pathway inhibitors increase bone 
morphogenic protein production as well [32-34].  Clinically, the activity of BPs has a 
profound effect on osteoporosis.  Clinical data demonstrate that BPs yield a 47% 
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reduction in vertebral fractures as well as wrist fractures, 50% in hip fractures, and a 19% 
overall drop in all nonvertebral fractures [35].  
 BP affinity to raw HAp is also clinically relevant in bone scintigraphy.  Tc99 
labeled methylene diphosphate (MDP) or hydroxy methylene diphosphate (HMDP) are 
used clinically for imaging bone abnormalities ranging from osteomyelitis to stress 
fractures.  In many bone diseases bone is deposited (as in a tumor) or degraded (as in 
osteoporosis and osteoarthritis).  Consequently, HAp crystals are exposed and can be 
targeted using bisphosphonates such as MDP (Figure 1.4). 
 The use of BPs as polymer/nanoparticle-targeting moieties has several advantages.  
nBPs contain a primary amine and can therefore readily be conjugated to carboxylic 
acids.  Secondly, as with tetracycline, if they are conjugated to nanomedicines via a 
degradable linker such as a pH sensitive hydrazone bond, they are pharmacologically 
active and may produce synergistic effects when coupled with appropriate drugs.  Finally, 
the patent protection of many BPs will expire soon, which makes them an economic 
option for a targeting moiety. 
 BPs are some of the most studied bone targeting molecules and much research has 
been done determining their binding properties to HAp [37-39].  Hrubý et al. determined 
that the number of targeting moieties on a polymer did not dramatically affect the rate of 
adsorption.  Rather, the amount of adsorbed polymer was affected by the number of 
targeting moieties, as more ligands yielded higher binding avidity.  The authors also 
concluded that there is a need for multiple targeting moieties to ensure that at least one is 
exposed [40].  Logically then, multiple targeting ligands become more critical as the 
nanomedicine size increases [41].   
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 BP adsorption to HAp is a thermodynamic process primarily driven by entropy.  
Mukherjee et al. measured the thermodynamics of adsorption for several clinically used 
BPs as well as modified BPs in order to determine what aspects of the molecules are 
important for HAp binding.  For instance, strongly basic side chain substituents, such as 
the nitrogen in alendronate, contribute dramatically to the binding in the free form.  
Furthermore, when measuring the difference between one Pi bond forming with HAp 
versus two Pi bonds forming (one phosphate versus both phosphates binding) they found 
that the hydroxyl group originating from the central carbon atom is necessary for both 
phosphates to bind [42].  By reducing a nanomedicine’s thermodynamic strength of 
adsorption, either by manipulating the number of ligands or by modification of the ligand 
itself, one can target only the thermodynamically favored diseased area over the 
kinetically favored skeleton. 
 Numerous BP conjugates with natural or synthetic macromolecules demonstrate 
bone targeting in vivo [43-45].  Targeted osteoprotegerin (OPG) is one example.  OPG is 
naturally produced by osteoblast’s Wnt-β-catenin signaling pathway and is a potent 
RANKL inhibitor preventing osteoclastogenesis.  With the intent to treat osteoarthritis, 
OPG was modified with a thiol-BP and administered intravenously (i.v.) to rats.  Overall 
bone deposition of BP-targeted OPG was twice that of free OPG.  In an osteoarthritis rat 
model, targeted OPG accumulated in the tibia 4x and femur 6x that of free OPG, 
demonstrating BP-targeting abilities [46]. 
 BPs exhibit antiangiogenic properties by causing apoptosis, inhibiting migration, 
and reducing angiogenic sprouts of endothelial tissue, making it a good antineoplastic 
agent but reducing capabilities to heal bones [47].  Moreover, the half-life of BPs such as 
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alendronate in the bone is more than 10 years [48].  The inhibition of osteoclasts for 
extended periods of time can have serious detrimental effects on bone turnover, as 
osteoclasts secrete insulin-like growth factors and BMPs to promote the maturation of 
osteons to osteoblasts.  Jawbones have a high blood supply and high turnover, resulting in 
BP accumulation.  The combination of low bone turnover and lower blood flow causes 
osteonecrosis of the jaw (ONJ).  ONJ is primarily associated, but not limited, to potent 
BPs used for chemotherapy, which completely inhibit osteoclast function [48,49].  Other 
toxicities include nephrotoxicity, hypocalcemia, and ocular dysfunction [50].  Therefore, 
BPs should not be used without considering some of the side effects.  
 
1.2.3 Acidic oligopeptides (AO) 
 Bone sialoprotein is one of several naturally occurring proteins that exhibit strong 
affinity for HAp.  Sialoprotein has several strings of acidic amino acids.  Modeled after 
sialoprotein, glutamic acid, and aspartic acid oligopeptides 4-10, amino acids (AA) long 
provide a more biocompatible option when adequate blood flow and bone turnover are 
needed [51].  Biocompatibility can be further increased as D peptides, which are not 
easily recognized by the body’s immune system, can replace L peptides.  Similarly to 
BPs, the HAp binding capabilities of these oligopeptides are retained after conjugation to 
a nanomedicine carrier via the peptide’s alpha amino group [52]. 
 AO’s chain length can be modified to fit an application.  Sekido et al. compared 
binding rates of Asp2-10 and Glu2-10 to HAp (Table 1.1).  Increase in AA chain length 
resulted in enhanced binding rate (Bmax) up to hexapeptides; then the rate of binding 
plateaued and further increase in chain length was without effect.  The dissociation 
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constant (Kd) decreased with increasing numbers of AA throughout the experiment and 
no differences were found between D and L AA.  This indicates that an AO over 6 AA 
long is ideal for optimal binding efficiencies [53].  Nanomedicines, however, are not 
limited to a single targeting moiety; rather, multiple ligands may also decrease Kd.  
Ouyang et al. demonstrated the effect of multiple sets of AOs on binding rates.  
Dendrimers were synthesized with 1, 2 and 3 chains of Asp4-6 and a HAp binding assay 
was performed.  The results indicated that two chains had nearly three times the binding 
of one alone but that the addition of a third chain resulted in poorer binding than two 
chains alone [52].  In the case of dendrimers, this means that steric hindrance may 
prevent binding of multiple AO chains.  The extra chains then decrease the binding by 
increasing the size of the dendrimer itself or by reducing the ionic attraction of other 
dendrimers to the HAp by increasing the negative charge on the surface. 
 
1.2.4 Estradiol analogs 
 Estrogen replacement therapy is being used for the treatment of osteoporosis related 
to low estrogen levels.  Crooks and coworkers developed estradiol analogs that would 
localize in bone tissue but are lacking estrogenic properties. They designed bone-
targeting compounds by attaching calcium chelators to an estradiol moiety through 
succinoyl [54] or carboxyethyl [55] linkers.  To further improve the targeting potential 
they prepared a series of phosphate esters of the carboxyethyl linker-containing 





1.2.5 Specific applications 
 Reflecting their molecular structures, tetracycline, BPs, and AO do have some 
unique binding capabilities, which may affect the disease states for which they are most 
appropriate.  The rate of binding of AOs to HAp is faster than that of BP [57].  One may 
hypothesize this to be a result of the larger binding area of AOs.  Meanwhile, BPs have a 
greater binding strength, most likely due to greater specificity of BPs for HAp [57].  
Wang et al. found that BP binds to all bone, while Asp8 binds preferentially to higher 
crystalline HAp and thus to resorption surfaces [58].  In a follow-up study, AFM 
cantilever tips were modified with either Asp8 or alendronate (ALN).  Interactions with 
HAp such as binding, adhesion events, and rupture forces were measured (Figure 1.5).  
ALN binding at zero distance was 190 pN, as opposed to 105 pN with Asp8.  Furthermore, 
ALN had higher rupture forces [3].  There were two sets of rupture forces for ALN, 
which lends itself to the bonding mechanism described by Mukherjee et al. [42].  Using 
two HA surfaces with differing crystallinity, Wang et al. confirmed that ALN is less 
affected by crystallinity and that Asp prefers higher crystalline HAp [3].  Bringing 
targeting via ionic interactions full circle, Miller et al. demonstrated using fluorescence 
microscopy that tetracycline deposits preferentially onto growing surfaces, or those with 
low crystallinity (Figure 1.6) [59].  Application of these principles means that targeting 
osteoclasts should be done with AOs, which prefer absorbing surfaces, while targeting 
osteoblast should be done with tetracycline, which prefers growing surfaces of bone. 
 
1.3 Polymer carriers 
 The conjugation of multiple targeting ligands to a polymeric backbone is an 
obvious advantage that polymeric drug delivery systems have over small molecule 
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systems.  In addition to targeting ligands, modification of polymer size has a profound 
effect on blood circulation time as well as on whole body biodistribution.  Once in target 
tissue, polymeric drug delivery systems have several modes of drug release, which range 
from passive diffusion from a degrading nanosphere to enzymatic cleavage of drug-
polymer linkers. These drug release mechanisms, in combination with biodistribution, 
play a critical role in ensuring the drug is delivered to the right area for the right duration 
of time. 
 
1.3.1 High molecular weight vs. low molecular weight carriers 
 The molecular weight and ultimately the hydrodynamic radius of polymeric 
carriers have a profound effect on the efficacy of drug delivery.  Higher molecular weight 
polymers have longer circulating half-lives and ultimately higher deposition in diseased 
sites.  However, as the molecular weight increases, so does uptake in the mononuclear 
phagocyte system (MPS).  Therefore, careful selection of molecular weights with 
appropriate targeting ligand concentration (number per macromolecule) is essential to 
ensure biocompatibility and high deposition of drug in the affected area.  Wang et al. 
compared 24 kDa, 46 kDa, and 96 kDa Asp8 containing HPMA copolymers in a 
biodistribution study.  Each polymer contained 4.4, 5.6, and 9.6 Asp8 chains per 
macromolecule, respectively.  Also included in the study was Tyr-D-Asp8 as a control.  
As hypothesized, the study demonstrated enhanced blood circulation time for high 
molecular weight conjugates, with the highest bone accumulation being 96 kDa HPMA 
copolymer by several fold.  However, the highest bone to MPS accumulation ratio was 
the Asp8 targeting ligand by itself, followed by 24 kDa HPMA copolymer conjugates 
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[58].  The same group performed a similar biodistribution study on ALN containing 
HPMA copolymers of two molecular weights – 20 kDa and 90 kDa.  In addition to 
molecular weight, the concentration of ALN (0%, 1.5%, and 8.5%) was also varied 
(Figure 1.7).  All conjugates showed an initially high uptake in the heart, lungs, and 
kidneys, which reduced over time.  Similarly to [58], the low molecular weight, 20 kDa 
conjugate cleared the body first as expected and each targeted molecule increased bone 
accumulation over time.  The high molecular weight (90 kDa) conjugate yielded a higher 
MPS uptake.  Similarly, higher ALN content also yielded higher MPS uptake.  This 
indicates that the identification of ideal targeting ligand concentrations needs to take into 
account the polymer’s overall charge (and therefore MPS uptake), number of targeting 
ligands per macromolecule (related to charge), and molecular weight.  In the case above, 
the drug with the highest bone to MPS ratio was the 20 kDa, 1.5% ALN polymer [60].  In 
conditions where metabolism of a drug by the MPS is a concern, moderate molecular 
weights with a low percentage of targeting moieties are beneficial.  However, uptake by 
the MPS generally means phagocytosis by mononuclear phagocytes.  Phagosomes 
eventually fuse with lysosomes, creating an acidic environment with several proteolytic 
enzymes.  Therefore, delivery of proteins and other molecules, which will be degraded by 
lysosomal enzymes, may not create biocompatibility issues following MPS uptake.  In 
these situations, a high molecular weight and a high targeting moiety content may be the 
best option. 
 
1.3.2 Degradable linkers 
 As critical as the biodistribution of a drug, the proper release rate and mechanism 
will determine the efficacy of a drug delivery system.  Modification of the linker, which 
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connects polymer with the drug, can create release profiles that deliver high amounts of 
drug immediately upon arrival or deliver small amounts over time, extending the 
effective dose time of the drug.  Furthermore, by utilizing bone-specific enzymes, 
disease-site-specific prodrugs can be created.  
 The bone itself has several enzymes, which can be used to release drugs.  Among 
these enzymes are matrix metalloproteinases (MMP) 1, 2, 3, 4, 7, 8, 9, 12, 13, and 14 and 
Cat K.  MMPs are expressed by osteoclasts and osteoblasts, and are overexpressed in 
many bone metastases [61-71].  Most MMPs function by cleaving peptide bonds holding 
collagen and other glycoproteins together.  MMPs assist osteoclasts’ function by 
degrading collagen within the bone at resorption lacunae while bone metastases use 
MMPs to degrade the basement membrane and spread throughout the body.  Using 
MMP-sensitive linkers may provide site-specific delivery of drugs to bone; however, 
bone delivery using MMPs is limited by the fact that MMPs are inhibited by tetracycline 
and derivatives such as doxycycline [72].  Cat K, on the other hand, is expressed in 
resorption lacunae and is not sensitive to tetracycline derivatives (Fig 1.1).  Due to 
secretion of Cat K into both the lacunae, Cat K-specific linkers are an excellent choice for 
signaling compounds such as prostaglandins and bone morphogenic protein-2 (BMP-2), 
whereas hydrazone bonds, disulfide bonds, and cathepsin B (Cat B)-sensitive linkers are 
better options for drugs such as chemotherapeutics, which rely on internalization by the 
cells prior to release.  
 Many classic degradable drug-polymer linkers rely on receptor-mediated 
endocytosis of cells or phagocytosis by osteoclasts.  Following endocytosis, the 
endosomal compartment acidifies and ultimately fuses with lysosomes into an acidic 
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organelle (pH ~5).  Acid-sensitive linkers are also effective in the low pH present in the 
interstitial space of tumors (pH 5-6) and the resorption lacuna of osteoclasts (pH 4-4.5) 
[73].  Hydrazone bonds are acid-sensitive linkers and are able to rapidly release an 
unaltered drug at pH 5.5, but remain intact at physiological pH 7.4.  Hrubý et al. 
conjugated doxorubicin to an HPMA copolymer using a hydrazone linker and measured 
release kinetics of the HAp adsorbed polymer as well as the polymer in solution at pH 5 
and 7.4.  Release kinetics at pH 5 was logarithmic, with over 95% of the copolymer 
conjugate in solution releasing the DOX within 10 h.  Release kinetics of the HAp bound 
polymer was slower, as after 10 h approximately 55% of the DOX was released and the 
remaining DOX was nearly all released over the first 50 h.  Meanwhile, at pH 7.4 the 
drug linker was relatively stable, only releasing 20% of the drug after 50 h [40].  
 There are other release systems that rely on the endosomal environment.  As the 
lysosome and endosome fuse, polymers within the endosome are exposed to proteases 
such as Cat B. Hrubý et al. also studied the release kinetics of a Cat B-sensitive 
tetrapeptide GFLG (glycine-phenylalanine-leucine-glycine) [74].  Release kinetics was 
nearly linear and much slower than the hydrazone bond discussed earlier.  When the 
polymer was in solution, after 50 h less than 45% of the drug was released.  Steric 
hindrance, preventing Cat B from accessing the tetrapeptide linker, reduced the DOX 
cleavage rate in HAp bound polymer to half the rate in solution, as only 22% was 
released after 50 h incubation [40]. 
 Elongated spacers, which separate the enzymatically cleaved bond from the drug by 
a self-eliminating group, were designed by several groups [75-79].  The predominant 
example of an electronic cascade spacer is the 1,6-elimination spacer [77].  It contains, 
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e.g., a bifunctional p-aminobenzyl alcohol group that is linked to an enzymatically 
cleavable group through an amine moiety.  After enzymatic cleavage, the strong electron-
donating amine group of the 1,6-elimination spacer is unmasked and immediately 
initiates an electronic cascade that leads to cleavage of the benzyl-carbamate bond and 
release of carbamic acid.  The unstable carbamic acid rapidly releases carbon dioxide and 
yields the unmodified drug [78,79].  Use of such spacers was shown in bone-targeted 
delivery of PGE1 [59] and anticancer drugs to bone [80-82]. 
 Once a polymer exits the endosome, it enters the cytosol.  The cytosol has a 
reducing environment that is able to reduce disulfide linkers.  Evidence also suggests that 
this reductive environment may start as early as the endosome during receptor-mediated 
endocytosis [83].  Kurtoglu et al. used disulfide linkers for dendrimer drug delivery and 
described the release at pH 5 and pH 7.4.  Using either cysteine or glutathione at pH 7.4, 
release occurred within 20 min, while at pH 5, complete drug release occurred over 6 h or 
more.  Furthermore, the amount of drug released was dramatically affected by glutathione 
and cysteine concentrations, as one cysteine can release only one drug [84]. 
 
1.3.2.1 Example of cathepsin K sensitive spacer design 
The design of an oligopeptide sequence susceptible to cleavage by Cat K is 
demonstrated here.  The aim was to design a conjugate that would deliver prostaglandin 
E1 (PGE1) to bone with subsequent PGE1 release by osteoclast-secreted Cat K in the 
resorption lacuna (for macromolecular entry into osteoclasts see [85-87]).   
 The Cat K-sensitive spacer was designed based on known interactions of peptide 
substrates with the active site of the enzyme [88].  The specificities of S1–S4 subsites 
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(subsite nomenclature from Schechter and Berger [89]) of the Cat K active site have been 
screened with positional scanning libraries [90].  Their most striking result was the 
unique preference for proline in P2 position; therefore, it was selected.  The favored 
amino acid residues in the P1 position were lysine and arginine.  However, to ensure that 
the spacer is stable in the circulation [91], basic amino acid residues have been avoided 
and norleucine, the most active neutral amino acid residue, was chosen for position P1.  It 
was shown that Gly-Pro in positions P3 and P2 were favorable for cleavage [90].  
Consequently, glycine was seleceted for position P3.  It had been observed previously 
that expanding the length of the oligopeptide spacer in side-chains of HPMA copolymers 
from three to four amino acid residues resulted in decreased steric hindrance upon the 
formation of the enzyme-substrate complex for chymotrypsin [92] and Cat B [74].  Thus, 
glycine was introduced into the position P4. 
 Chemically, the C end of Gly-Gly-Pro-Nle spacer cannot be directly connected to 
PGE1 because the latter lacks a NH2 group.  To overcome this problem, a 1,6-elimination 
spacer based on 4-aminobenzyl alcohol (AB-OH) was inserted.  The latter was used to 
link the peptide to the C-1 COOH group of PGE1.  Upon enzymatic cleavage of the 
peptide spacer, the strong electronic-donating amine group of the 1,6-elimination spacer 
is unmasked [75,76] and initiates an electronic cascade that leads to the cleavage of the 
ester bond and immediate release of unmodified PGE1 (Figure 1.8).  Finally, a 
methacryloyl group was attached at the N-terminus of the construct; the resulting 
macromonomer, MA-Gly-Gly-Pro-Nle-AB-PGE1, may be copolymerized with HPMA to 
produce new PGE1-containing macromolecular therapeutics.  The release of PGE1 from 
HPMA + MA-Gly-Gly-Pro-Nle-AB-PGE1 copolymer indicated that a high rate of 
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cleavage occurred in osteoclast cultures followed by osteoblast cultures.  Polymer 
incubation with nonskeletal and precursor cells resulted in minimal release of PGE1, 
demonstrating the specificity of this linker [93].  The specificity of the linker was also 
validated in vivo [59,80,81]. 
 
1.3.3 Different polymers studied 
 Each polymer exhibits unique characteristics based on chemical and structural 
properties.  We have classified polymers by their structural properties according to 
whether they form linear hydrophilic polymers or spherical micelle and nanoparticle 
structures. 
  
1.3.3.1 Linear polymers 
1.3.3.1.1 Cationic polymers  
 Polyethyleneimine (PEI) and poly(L-lysine) (PLL) are frequently-used cationic 
polymers in drug and gene delivery systems.  Uludaǧ and coworkers incorporated a BP, 
2-(3-mercaptopropylsulfanyl)-ethyl-1,1-bisphosphonic acid, to both polymers using 
heterobifunctional reagents.  In vitro (HAp) and in vivo (unprocessed bone matrix from 
femurs/tibiae) mineral affinity of BP containing polymers was evaluated and compared 
with unmodified polymers.  Interestingly, they found that in vitro binding to HAp was 
similar or lower after conjugation to BP and that both PEI and PLL were able to bind 
nearly 100% to HAp in many conditions on their own.  This is not surprising, as 
positively charged molecules should adsorb to HAp.  In vivo results on a rat model also 
showed no significant difference in bone affinity of modified and unmodified polymers 
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[94].  In addition, PEI and other cationic polymers are associated with toxicity in vivo 
[95,96]. 
 Recently, modified PEI was used for the development of bone-seeking 
radiopharmaceuticals.  To this end, PEI was functionalized with methylene phosphonate 
groups, thereby incorporating targeting and metal chelating ability in the polymer itself.  
In vitro tests demonstrated that fractionated N,N’,N’-trimethylenephosphonate-
poly(ethyleneimine) (PEI-MP) was able to carry radioactive tin ions to an HAp surface 
and then release them upon contact.  By doing so, PEI-MP may work well as an imaging 
agent and as a possible radiotherapy delivery agent for metastatic bone cancer [97,98].  
As such, prevention of any biocompatibility issues may be avoided by integrating PEI-
MP into a block-copolymer of a more biocompatible polymer.  
 
1.3.3.1.2 Poly[N-(2-hydroxypropyl)methacrylamide]   
 HPMA is one of the more studied polymer therapeutics to bone.  PolyHPMA’s 
biodistribution and bone-targeting abilities have been well documented and are discussed 
throughout this paper [58-60,80,81].  Other advantages of HPMA copolymers include a 
low toxicity profile and the ability to control the molecular weight and therefore 
biodistribution by RAFT polymerization [99-101].  This process also permits the 
incorporation of methacryloylated drug derivatives into the polymer by copolymerization 
[99,100], eliminating the chance of having unreacted (residual) groups remaining on the 
polymer backbone after postpolymerization modification.  HPMA copolymers have also 




1.3.3.1.3 Other polymer carriers  
 Korzhikov et al. synthesized aldehyde-containing copolymers based on 2-deoxy-2-
methacrylamido-D-glucose (MAG).  Two methods were used for the introduction of 
aldehyde groups into the polysaccharide chains: i) copolymerization of MAG with N-
vinylpyrrolidone and a comonomer that can be easily converted to an aldehyde, such as 
diethylacetal acrolein; and ii) the periodate oxidation of the saccharide units. The water-
soluble polymers adsorbed on HAp.  The ultimate aim is to use these polymers for 
construction of composite scaffolds for tissue regeneration [105]. 
 Wang and coworkers synthesized a polyrotaxane delivery system targeted by ALN.  
They conjugated ALN to α-cyclodextrin and threaded it onto PEG (2000 mol. wt.) 
producing a pseudopolyrotaxane.  Then, employing copper(I)-catalyzed Huisgen 1,3-
dipolar cycloaddition, the pseudopolyrotaxane was copolymerized with bulky monomers 
containing imaging and/or therapeutic agents.  The osteotropicity of the constructs was 
confirmed in vivo [106]. 
 
1.3.3.2 Vesicular polymer carriers 
1.3.3.2.1 Micelles and liposomes 
 Micelles and liposomes are able to hold a great deal of drug when compared to 
linear polymers due to their three-dimensional shape.  Although in vivo stability may be 
an issue for many polymeric spherical micelles and liposomes, these delivery systems are 
able to release their contents over long periods of time [107,108].  Finally, as alluded to 
before, this class of drug carriers may be able to protect drugs they carry from 




 Critical to their success, bone-targeted liposomes are able to retain their targeting 
ability.  Hengst et al. designed a 1,2-diacyl-Sn-glycero-3-phosphocholine (EPC) liposome 
containing a BP targeting agent anchored by cholesterol.  Each of the four conjugates 
tested had a low polydispersity of ≤0.1.  Mole percents of the targeting ligand, 
cholesteryl-trisoxyethylene-bisphosphonic acid (CHOL-TOE-BP), were 0%, 3%, 14%, 
and 25% with zeta potentials of -18 ± 2, -28± 1, -34± 2, and -40± 2, respectively.  The 
determination of the binding of each liposome revealed that 50% HAp binding was 
achieved using the 3 mol% CHOL-TOE-BP and binding progressed nearly linearly until 
100% binding was achieved using the 25 mol% CHOL-TOE-BP liposome.  This data 
suggests the bone targeting potential of this liposome [109]. 
 Uludaǧ and coworkers incorporated BP-derivatized liposomes into 
collagen/hydroxyapatite scaffolds and decreased the rate of model drug release from the 
constructs.  This provides a sustained drug release approach for bone regeneration [107]. 
 The liposomal drug formulations for the treatment of rheumatoid arthritis vary from 
the scope of this chapter but have been recently reviewed [110]. 
 
1.3.3.2.2 Poly(lactic-co-glycolic acid)(PLGA) nanospheres  
 Poly(lactic-co-glycolic acid)(PLGA) nanospheres are a well-studied drug delivery 
modality that has been applied to bone targeting.  Choi et al. designed PEG-PLGA block 
copolymers intermixed with ALN-functionalized PLGA to create surface-modified 
nanoparticles.  The monomethoxy PEG formed a hydrophilic layer on the surface of 
nanoparticles with the potential to decrease MPS accumulation, and ALN was used as the 
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targeting moiety.  The study of the relationship between structure and adsorption on HAp 
revealed decreasing adsorption correlated with a decreasing concentration on ALN at the 
surface; the increase in PEG mol. wt. (550, 750, and 2000) resulted in decreased 
adsorption apparently due to shielding of the ALN moieties by longer PEG chains [41].  
As PLGA degradation yields naturally occurring products, it also has a low toxicity 
profile.  Cenni et al. were able to synthesize ALN-functionalized nanospheres with a 
polydispersity index of 0.348 ± 0.020 nm and test their toxicity.  Each in vitro test 
(hemolysis, leukocyte proliferation, platelet number, coagulation, and complement 
consumption) showed acceptable blood compatibility and an absence of cytotoxicity 
[111].  In follow-up studies, the authors loaded ALN-functionalized PLGA nanoparticles 
with doxorubicin (DOX) and evaluated their properties in an orthotopic mouse model of 
breast cancer bone metastases.  Both free DOX and DOX-loaded nanoparticles reduced 
the occurrence of metastases in mice.  Loaded and drug-free nanoparticles decreased the 
number of osteoclasts at the tumor site; the authors hypothesized that this may be the 
result of ALN activity [112]. 
 Other advantages of PLGA include well-studied drug release kinetics.  By 
modification of lactic glycolic acid ratios, PLGA nanospheres can release their contents 
over a wide time scale [113-115].  More in vivo tests such as bone targeting and whole 
body biodistribution are needed, however, in order to truly determine the efficacy of 






1.3.3.2.3 Other vesicular structures 
 Ozcan et al. used nanoprecipitation to produce poly(γ-benzyl-L-glutamate) (PLGB) 
nanoparticles (< 80 nm; low polydispersity), which were functionalized with PEG-ALN 
for bone targeting.  ALN presence did increase bone targeting dramatically in vivo.  By 
labeling the PBLG-PEG-ALN nanospheres with FITC, Ozcan et al. were able to 
demonstrate preferential accumulation of targeted drug in bone [116]. 
 Wang et al. evaluated bovine serum albumin (BSA) nanoparticles surface-coated 
with PEI-PEG-thiolBP and used them for the delivery of bone morphogenetic protein-2 
(BMP-2).  They found that the nanoparticles were not effective in bone targeting after i.v. 
administration.  However, they were useful in localized delivery of BMP-2 in bone repair 
and regeneration [117]. 
 
1.3.4 Dendrimers, dendrons, dendronized polymers 
 Dendrimers are symmetrical vesicular carriers, whereas dendrons are tree-like 
fragments of dendrimers that can be attached to water-soluble polymers [118].  Thus, the 
“dendron-like” systems possess complex structures characterized by high density of 
functional groups and/or targeting moieties.  Ideally (without structural defects), 
dendrimers are monodisperse, spherical compounds.  Their size depends on the 
generation, i.e., the number of successive synthetic steps used.  Numerous attempts have 
been made to exploit dendrimers in drug delivery, including targeting to bone.  Ouyang et 
al. synthesized naproxene containing polyamide and poly-ether-amide dendrimers and 
decorated them with 2 or 3 Asp(4-6) peptides and demonstrated affinity for HAp [52].  In 
the following study the same group synthesized the “next generation” of naproxene 
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containing dendritic compounds with four or eight Asp(4-6) fragments.  They did not 
observe a difference in HAp binding of constructs containing low or high Asp(4-6) content, 
and the total HAp binding only ranged from 63% to 75% [119].  Clementi et al. 
synthesized PEG-based dendrimers from heterobifunctional PEG; they were decorated 
with H2N-PEG-b-Glu-(b-Glu)2-(COOH)4, exposing four carboxylic groups for the 
attachment of ALN and/or paclitaxel.  This construct was able to achieve nearly 100% 
HAp binding and nearly 80% HAp binding following conjugation to paclitaxel (PTX).  
These conjugates were designed for the treatment of bone neoplasms and used a pH-
sensitive linker for rapid release of the drug.  In vitro studies demonstrated that drug 
release was highly effective, resulting in conjugated PTX having a similar IC50 as PTX 
alone, apparently due to fast drug release at physiological pH [120]. 
 
1.3.5 Vesicular vs. linear polymer carriers 
 The decision to use a spherical or linear polymer depends on the application.  Both 
types can be designed so that they release drugs rapidly.  Longer periods of time (such as 
a day to a week) may be achieved using linear polymers conjugated to drugs via enzyme- 
degradable linkers.  For periods over a week, spherical polymers may be designed to 
release drug as the polymer degrades.  The question then arises as to which yields better 
targeting and how it affects the treatment of disease.  This may be answered by looking at 
zeta potentials.  Excess surface charge is associated with high MPS uptake [121].  This 
means that for a specific polymer at a specific hydrodynamic radius, the addition of 
surface charge, in this case as a targeting moiety, could increase MPS uptake.  As such, 
linear polymers may have an advantage.  Linear polymers are able to bend and conform 
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to a surface, thereby reducing the number of targeting moieties needed to achieve bone 
specificity.  Spherical polymers, on the other hand, have a three-dimensional shape, 
which reduces the amount of surface that can bind to bone, thereby increasing the need 
for several targeting moieties and increasing the zeta potential.  Though this theory needs 
to be tested, one may consider that if MPS uptake does not contribute to a decrease in 
biocompatibility (such as with drugs that can be degraded by MPS lysosomes), then a 
spherical polymer as well as a linear polymer would work.  However, if MPS uptake 
results in toxicity, as with nondegradable chemotherapeutics, then one may consider the 
use of a linear polymer over a spherical one. 
 
1.4 Therapeutics 
 Life expectancy in the developed world continues to increase at a constant rate 
[122]. As such, age-related health complications also increase and the need for 
therapeutics to treat bone degenerative diseases and cancers expands.  Critical to solving 
problems associated with bone disease is the selection of proper therapeutics.  Bone 
disease causes a wide range of problems: too little bone growth, cancer and overgrowth, 
inflammation, and infection.  In this paper, focus will be on bone anabolic agents (for 
osteoporosis) as well as cytotoxic agents (for cancer).  Other topics, such as inflammation 







1.4.1 Osteoporosis and other low bone mineral density (BMD)  
related diseases 
 Osteoporosis is among the most common of the degenerative diseases.  It is 
estimated that 1 out of 5 women over the age of 50 have osteoporosis and that 
approximately half of the women over 50 will fracture their hip, wrist or vertebra [125].  
BPs, although helpful for some people, have several side effects, as described previously 
(section 2.3).  Furthermore, a need exists for alternatives to Cat K and RANKL inhibitors 
[126-130].  Ultimately, these drugs yield inadequate bone turnover and therefore poor 
bone quality.  The 1-34 fragment of recombinant parathyroid hormone (PTH), FDA 
approved in late 2002, is an effective bone anabolic agent.  When compared to oral 10 
mg/day ALN, the administration of s.c. injections 40 µg/day PTH yielded greater bone 
density [131].  However, there is a concern that lifelong injections may cause 
osteosarcomas to develop, and consequently, the drug may only be prescribed for 2 years 
during one’s lifetime [132].  Other bone anabolic agents have also been investigated for 
treatment of osteoporosis but ultimately have significant drawbacks preventing their use.  
Prostaglandins are in clinical use for several medical conditions.  In bone, they exhibit 
strong anabolic effects; however, the short half-life and serious cardiovascular side 
effects of free prostaglandins have prevented their use in osteoporosis.  BMPs have been 
clinically applied to fuse vertebrae.  BMPs have low systemic side effects, which may be 
in part due to their short blood half-life, which prohibits effective systemic 
administration.  Targeting bone anabolic agents and/or extending their circulation half-




1.4.2 Anabolic agents 
 Several potential bone anabolic agents exist. We will discuss their interactions in 
the hopes of elucidating possible synergistic mechanisms, which may be employed to 
create superdrugs (Figure 1.9). 
 
1.4.2.1 Prostaglandins 
 Prostaglandins (PGEs), especially the E series (such as PGE1 and PGE2), have been 
studied extensively for their bone anabolic properties.  Their importance in bone turnover 
is demonstrated by the lack of bone repair when patients are administered NSAIDs [133-
137]. Systemically administered prostaglandins, however, cause diarrhea, lethargy, and 
flushing and thus are too toxic for nonlocal or nontargeted dosing [138].  Locally 
administered to bone, PGE affects osteoblasts by binding to four receptor subtypes (EP1-
4) of PGEs.  EP2 and EP4 are the primary receptors associated with bone turnover; EP2 is 
normally associated with bone anabolism and EP4 generally affects catabolism by 
upregulating RANKL through the MAPK pathway [139-143].  Both EP2 and EP4 have 
traditionally been associated with a dramatic increase in cAMP levels; however, these 
two receptors also contribute to the p38 MAPK and ERK MAPK signaling pathways, 
respectively [144].  There is also evidence that prostaglandins upregulate BMP-2 
production [32]; however, another study contends that it is not through EP2 or EP4 [144].   
 Several studies have attempted to treat osteoporosis by either modification of PGE2, 
making it specific for EP2 or EP4 receptors, or by conjugation to targeting moieties 
[59,138,145,146].  Miller et al. have attached PGE1 via a Cat K sensitive spacer, Gly-
Gly-Pro-Nle, to an HPMA copolymer (Mw 37.2 kDa), P-Asp8-FITC-PGE1.  
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Ovariectomized female Sprague-Dawley rats were administered a single i.v. bolus of 
either 10 mg P-FITC, P-Asp8-FITC or P-Asp8-FITC-PGE1 (0.61 mg of PGE1 equivalent), 
followed by a tetracycline label administration at the end of the study on day 25.  
Measuring the distance between the FITC-labeled polymer and the tetracycline label on 
the bone surface, they were able to determine the surface-referent bone formation rates 
(µm2 µm-1 day-1).  Bone deposition rates attributed to P-FITC, P-Asp8-FITC or P-Asp8-
FITC-PGE1 were 0.0362 ± 0.0062, 0.0541 ± 0.0108, and 0.1142 ± 0.0077, respectively, 
demonstrating the potential anabolic effects of targeted PGE1 against osteoporosis [59]. 
 
1.4.2.2 Statins/bisphosphonates 
 Statins and BPs affect bone turnover by interacting with the mevalonic acid 
pathway and down-regulating protein prenylation.  It is believed that down-regulating 
protein prenylation down-regulates RhoA and by so doing upregulates eNOS.  The 
presence of eNOS increases synthesis of BMP-2 and therefore increases bone anabolism 
[147,148].  Furthermore, statins and BPs may also directly upregulate the PGE pathway, 
as COX-2 inhibitors dramatically reduce statin-induced bone anabolism by up to 77% 
[149].  Statins also induce VEGF, which contributes to osteoblast differentiation 
[150,151].  Statins, having been administered systemically for lowering cholesterol, also 
affect bone growth.  Clinical evaluation of systemic delivery has shown no decrease in 
fractures, minimal increase in BMD, and no increase in bone turnover markers in 
postmenopausal women [152,153]; however, local administration in animals has shown 
significant bone turnover [33,154-158].  Systemic delivery of bone-targeted statins may 
increase local bone concentrations enough for higher BMD and bone turnover.  
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1.4.2.3 TGFβ superfamily  
 BMP-2 is a member of the TGFβ superfamily.  It is produced by osteoclasts and the 
signal differentiation of osteoblasts through the SMAD5/8 pathway.  SMAD5/8 combines 
with SMAD1 and translocates to the nucleus where Cbfa1/Runx2 is upregulated.  
CBFA1/Runx2 is responsible for promotion of several osteoblast differentiation genes as 
well as the upregulation of COX2 [159].  Although overlap can be seen in the two 
pathways, BMP-2 operates seperately from PGE.  Research suggests that BMP-2 has a 
synergistic effect with PGE [160].  BMP-2 is clinically applied locally for spinal, oro-
maxillary, and trauma surgeries [161-169].  Also part of the TGFβ superfamily, TGF-β1 
and IGF-I are produced by osteoclasts [15] and affect transcription via several SMAD 
proteins.  TGF-β1 and IGF-I activate NFκB, leading to increased levels of COX-2 and 
PGE2 production [170,171].  TGF-β1 is generally considered to inhibit osteoclasts, 
however, as with many growth hormones, their action is dose-dependent [172-174]. 
 
1.4.2.4 Fragment 1-34 of parathyroid hormone (PTH) 
 PTH1-34 (PTH contains 84 AA) is prescribed for treatment of osteoporosis.  
Systemically, PTH1-34 affects calcium resorption in the kidneys and intestine [175].  
Within bone, PTH 1-34 affects osteoblasts and leads to increased cAMP/PKC production 
and differentiation even when COX-2 is inhibited [176].  Increased cAMP levels also 
open up calcium channels, leading to increased calcium levels in the cell.  Consequently, 
the calcineurin pathway is triggered, which activates NFAT and yields increases in COX-
2 expression [177].  Elevated levels of PTH1-34 reduce apoptosis by increasing PKC 
levels there by upregulating FOXO3a DNA repair mechanisms [178].  Overexpression of 
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cAMP/PKC leads to deleterious proteasomal (smurf1) degradation of CBFA1/Runx2, and 
therefore, regulation of BMP-2 effects [179-181].  Furthermore, proteosomal degradation 
will negate the anti-apoptotic effects of FOXO3a [182].  Therefore, intermittent 
administration of PTH1-34 leads to anabolism, while chronic administration leads to 
catabolism [183]. 
 
1.4.3 Delivery of proteins 
 Numerous attempts have been made to modify protein-based therapeutics with 
bone-seeking moieties to enhance their localization at skeletal sites [11,12,184].  Bansal 
et al. synthesized clustered BP-based targeting moieties composed of four bisphosphonic 
acid moieties linked through a benzene ring and conjugated them to bovine serum 
albumin (BSA) as a model protein.  In vitro binding in both saline and 60% serum 
solutions resulted in less than 60% bound protein.  However, in vivo results indicated a 
4.7-fold increased accumulation in rat tibiae over controls (BSA and BSA targeted with a 
thiol-BP moiety).  Thus the clustered BP possessed a considerably increased bone-
seeking capacity in vivo when compared to HS-BP [185].  Interestingly, the accumulation 
of thiolBP modified osteoprotegerin in osteoarthritic rats undergoing active bone 
remodeling increased more than 4x over that of control unmodified OPG 24 h after i.v. 
administration [186]. 
 Proteins such as BMP-2 have a circulation half-life of only about 1 min [187].  For 
successful systemic administration they may have to be modified by semitelechelic (ST) 
water-soluble polymers.  It is well known that covalent attachment of PEG [188] or ST 





1.4.4 Bone metastases 
 Paget’s 1889 “seed and soil” theory of bone metastases remains the generally 
accepted theory regarding metastasis locating to bone.  This theory simply reasons that as 
metastatic cells (the seeds) enter into the bloodstream they will be carried everywhere, 
but they will only attach and grow where the conditions are right (the soil) [190].  
Examples of this include bone marrow expression of CXCL12 [191,192], whose 
complementary CXCR4 is found on several prostate and breast cancers [193-195].  Once 
in the bone, bone anabolism and catabolism causes patients severe bone pain and 
increased mortality [196].  Treatment of these metastases often involves small molecule 
therapeutics, which target various osteoclast mechanisms.  Several small molecule 
osteoclast-targeted therapeutics have been studied: vacuolar H+-ATPase inhibitors, 
Reveromycin A, Methyl Gerfelin, C-Src Inhibitors, aVb3 integrin inhibitors, Cat K 
inhibitors) [197] and BPs [50].  Although these do reduce bone pain and some degree of 
metastatic growth, their effects may be increased as other synergistic drugs are added to 
reduce growth and tumor progression. 
 As bone metastases progress, HAp is exposed, providing a target for BP attachment 
[198].  The Satchi-Fainaro group conducted several experiments combining the anti-
angiogenic properties of ALN with other chemotherapies.  Paclitaxel (PTX) has anti-
angiogenic properties in low doses.  They used ALN-targeted PTX containing HPMA 
copolymers to reduce migration and proliferation of human umbilical vein endothelial 
cells (HUVEC).  Cat B is a protease expressed by both proliferating endothelial and 
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prostate cancer cells.  Thus they incorporated a Cat B sensitive linker (GFLG) for both 
PTX and ALN.  In vitro data suggest that the HPMA copolymer inhibited migration and 
proliferation of both human prostate adenocarcinoma (PC3) and HUVEC cells [199]. 
 In a follow-up study, Miller et al. demonstrated the in vivo tumor inhibition and 
safety profiles on Balb/c mice.  The PTX, ALN, HPMA copolymer showed no significant 
WBC toxicity, while free PTX significantly reduced WBC counts.  Intratibial injections 
of mCherry-labeled 4T1 cells were used to mimic breast cancer metastasis to the bone.  
Following i.v. administration of either PTX, ALN HPMA copolymer or free PTX+ ALN 
in combination, the polymer conjugate inhibited tumor growth by 60%, while free PTX + 
ALN only inhibited 37% as compared to controls [200].  
 Segal et al. conducted a similar set of experiments using TNP-470 bound to an 
HPMA copolymer conjugate targeted with ALN.  TNP-470 demonstrated high efficacy in 
clinical trials, but too many side effects prevented clinical applications [201].  Segal et al. 
sought to reduce TNP-470 side effects by conjugation and targeting.  Both ALN and 
TNP-470 were conjugated to HPMA copolymer using Cat K sensitive linkers (Gly-Gly-
Pro-Nle).  In vivo studies demonstrated (Figure 1.10) that not only do ALN and TNP-470 
have synergism, but revealed that the HPMA copolymer decreased osteosarcoma growth 
by 96% compared to the control, as opposed to 45% with free ALN in combo with TNP-
470 [80].  Similar to the PTX, ALN, HPMA copolymer, TNP-470, ALN HPMA 
copolymer’s toxicity is low, as opposed to ALN + TNP-470, which caused in vivo weight 





1.4.5 Radiation therapy 
 Targeted delivery of radioisotopes provides opportunities to open up the field of 
theranostics.  Several groups have effectively reduced tumor size and alleviated bone 
pain by radiolabeling BPs [202,203].  PEI-MP bound tin is one of the few studies which 
uses polymer attributes in radiation therapy to bone.  Jansen et al. demonstrated effective 
HAp binding of Sn2+ and Sn4+ chelated PEI-MP.  In order to demonstrate the EPR effect 
in combination with HAp adsorption, however, an in vivo study is still necessary [97,98].  
Although more tests are needed in order to determine the efficacy of delivering 
radiolabeled polymers to bone metastases, one must still be curious about the 
possibilities.  Although radioactive polymers may need to be kept small as to reduce 
circulation time, one may still see greater tumor accumulation due to the EPR effect.  
Furthermore, the dose can be increased with polymer therapeutics, as several chelating 
moieties can be attached to one molecule.  Finally, a single polymer may be able to 
destroy cancer stem cells by radiosensitizing a tumor using a compound such as perifosin 
and then killing the stem cells using radiation [204]. 
  
1.5 Conclusions 
 Targeted polymer therapeutics continue to find niches in the medical world.  Much 
of this research has focused on the EPR effect and delivery of chemotherapeutics and 
siRNA to solid tumors.  Although this is excellent research, the characteristics of bone 
supply a fertile ground for future clinically relevant targeted polymer drug research.  
Many applications favor macromolecular drug delivery over small molecule drugs.  For 
example, one must consider that achieving the highest binding constant possible may not 
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suit one’s needs.  Having an extremely low dissociation constant means that the polymer 
will most likely bind kinetically to the first bone that it comes in contact with.  
Modification of mole percent targeting ligands, or the ligand itself may reduce the Kd, 
thereby favoring thermodynamic adsorption over kinetic adsorption.  By doing so, one 
may reduce promiscuity of the targeting ligand by limiting adsorption to the diseased 
area, such as a tumor.  This method of targeting lends itself to targeted polymer 
therapeutics rather than their small molecule counterparts.  Furthermore, many bone 
diseases are chronic conditions.  Osteoporosis and osteoarthritis sufferers would benefit 
from extended controlled drug release mechanisms, which suit macromolecular drug 
delivery systems.  As an underutilized application for targeted polymer drug delivery, 
bone-targeted polymer therapeutics have yet to reach their full potential. 
 
1.5.1 Gaps in current research 
 Many novel bone-drug applications have yet to be explored, but first it is important 
to better develop disease-specific targeting and discover specific biochemical pathways 
involved in disease states.  More accurate targeting to specific diseases involves finding 
out what bone conditions are present in each disease and then tailoring targeting 
mechanisms to those conditions.  In this chapter we discussed several mechanisms by 
which modification of targeting mechanisms will lead to drug accumulation on varied 
HAp crystalline states.  Currently, most papers stop prior to in vivo data, and pre-in vivo 
binding studies use a standard HAp.  Appropriate pre-in vivo testing should include 
binding assays using HAp crystals sized for specific disease conditions.  Information also 
lacking with regards to many bone diseases is a deep understanding of the pathology and 
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biochemistry that govern each disease.  For example, this paper discussed some of the 
basic principles of bone anabolism affecting diseases such as osteoporosis.  Some 
crosstalk between signaling pathways such as BMP-2 and PGEs were discussed, but great 
gaps in our knowledge remain.  Studies such as Lee et al., where basic research on bone 
anabolic pathways are elucidated, can be performed side-by-side with applied research on 
discovering novel delivery approaches and are critical for progression of the field [115].  
The realization of synergistic drugs delivered to bone depends on this basic research. 
 
1.5.2 Future of the field 
 With attention to proper targeting techniques, bone-targeted therapeutics has several 
functions it can fulfill.  Relatively few novel developments of bone-targeted 
antineoplastic agents delivered by polymers have been explored.  Bone metastases are 
manifestations of severe cancers, representing a largely unsolved problem in oncology.  
As such, small improvements may go a long way in the clinic.  As previously discussed, 
locally applied radiation therapy delivered with a sensitization drug, or two 
chemotherapeutics acting on different pathways are a good place to begin in solving this 
problem. 
 Combination therapies can also be applied to osteoporosis.  It is clear that 
combining drugs such as BMP-2 and PGE2 is worth exploring, but dosing regimens may 
also yield some dogma-changing discoveries.  Development of bone anabolic agents for 
the treatment of osteoporosis has always been a tricky balancing act.  As seen with 
PTH1-34, overstimulation of an anabolic biological pathway over time can result in 
osteosarcoma.  Reducing the chance of osteosarcoma may be accomplished by the 
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development of several targeted bone anabolic agents that affect different pathways and 
by applying them over different lengths of time, never exacerbating one particular 
pathway. 
 Lessons learned from targeting osteoporosis may then be applied to developing 
anabolic agents to aid healing following orthopedic surgeries and reduce long-term bone 
resorption around prosthetic stems.  Furthermore, treatment of deep bone infections may 
be reduced by a pre- and postsurgery targeted antibiotic rather than antibiotic-loaded 
bone cements, which some argue have toxicity issues.   
 Bone diseases continue to increase in prevalence with aging populations.  
Successful advancements in bone-targeted polymer therapeutics will yield clinically 
relevant drugs that will reduce pain and increase quality of life for millions of people.  
 
1.6 Statement of objectives 
The primary objectives of the project are to develop a bone-targeted micellar drug 
delivery platform.  This basic construct focuses on multifunctionality of each component 
to ensure simplicity of the final product.  The targeting ligand aspartic acid octapeptide 
functions as both a targeting moiety as well as the corona of the micelle.  In addition, the 
drug payload is covalently bound to the micelle by a hydrolyzable linker, and both 
functions as a therapeutic and stabilizes the micelle core.  The micelle then features a 
flexible hydrophilic linker between the targeting ligand and a hydrophobic tail for 
increased stability.  Our goal is to demonstrate this micelle construct’s efficacy in 
osteosarcoma and bone fractures.   
This project tested two main hypotheses: 
		
36	
1. The conjugation of a hydrophilic targeting ligand and a hydrophobic drug will 
self-assemble into a micelle. 
2. Aspartic acid octapeptide has sufficient bone affinity to accumulate in a bone 
fracture callus.  
In order to test these hypotheses the following specific aims were proposed: 
1) Synthesize and characterize doxorubicin-containing micelles. 
a) Synthesize four micelles with varying unimer hydrophobicity and head group 
branching. 
b) Determine if the micelles provide sufficient size, shape, and stability for 
extended blood circulation. 
c) Measure the micelle’s potential to bind to hydroxyapatite and release 
unmodified doxorubicin under desired stimuli. 
2) Synthesize and characterize fracture-targeted micelles. 
a) Select two micelles from aim 1 and modify them with a bone anabolic agent. 
b) Confirm that the structure retains the ability to form micelles and release 
unmodified drug. 
3) In vivo biodistribution and treatment. 
a) Radio-iodinate the drug on the micelles. 
b) Measure the micelles’ biodistribution compared to free drug at 1 h, 4 h, and 24 
h. 
c) Measure the micelles’ ability to heal fractures against free drug and PBS 
control. 
The Kopeček research group has extensive experience in macromolecular drug delivery, 
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including delivery to bone.  The group’s advances in treating osteoporosis has inspired 
interest in developing drug delivery systems aimed at other bone diseases.  The theories 
tested in this dissertation were built on several of the concepts developed while studying 
osteoporosis, namely that aspartic acid octapeptide can target exposed hydroxyapatite, 
and that some bone anabolic agents elicit better responses when targeted by this method.  
In the following chapters we have demonstrated that in testing our main hypotheses by 
completing the designed aims that a micellar drug delivery system can be modified to 
accommodate treatment of multiple diseases.  Furthermore, with very little development 
in targeting anabolic agents to bone fractures, these milestones are sufficient to command 
more development of the field.  
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Figure 1.1. General osteoclast structure and function demonstrating unique 
environments, which can be utilized for site-specific release of drugs.  Osteoclasts 
sequester portions of bone by sealing off areas called lacunae.  The adjacent membrane to 
the bone ruffles and releases cathepsin K and HCl, reducing the pH to 4-4.5 and 
dissolving the bone.  Calcium from the bone is then transported to the secretory domain 
and released into the interstitial space.  Although not specific to osteoclasts 
endosomes/lysosomes reduce pH to 5-6 and contain cathepsin B, two environmentally 





Figure 1.2.  General structure of bone-targeted polymeric nanomedicines. 
 
  
Figure 1.3. Structures of several bone-targeting molecules, including tetracycline as 
well as minimalized tetracycline (3-amino-2,6-dihydroxybenzamide) and its conjugate 
with estradiol [29].  Also shown are the structures of several bisphosphonates in 
comparison with pyrophosphate.  Acidic oligopeptides such as aspartic acid (shown) or 
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Figure 1.4.  MDP-Tc99 scan demonstrates the targeting specificity of bisphosphonates.  
Shown here is a primary osteogenic sarcoma from a 72-year-old man with Paget’s 
disease.  Dark arrows indicate a metastasis to inguinal lymph node.  Reprinted with 





Table 1.1 Maximal binding rate (Bmax) and dissociation constant (Kd) of acidic 
oligopeptides with increasing number of amino acids. 
 
Compound Kd (µM) Bmax (nmol/h/100µg HAp) Bmax/Kd 
Fmoc-(L-Asp)n    
n=2 >100 n.d.  
4 12.1 ± 1.3* 0.34 ± 0.04 0.028 
6 6.03 ± 0.84 1.57 ± 0.16 0.026 
8 5.24 ± 0.55 1.61 ± 0.18 0.307 
10 2.52 ± 0.23 1.66 ± 0.17 0.659 
Fmoc-(L-Glu)n    
n=2 >100 n.d.  
4 13.2 ± 1.1 0.42 ± 0.05 0.032 
6 6.38 ± 0.71 1.59 ± 0.17 0.249 
8 5.21 ± 0.61 1.61 ± 0.13 0.309 
10 2.39 ± 0.25 1.66 ± 0.16 0.695 




Figure 1.5. Atomic force microscopy histograms demonstrating rupture forces of (A) 
alendronate and (B) D-Asp8 modified cantilever tips from a tooth enamel surface. (C) 
Binding ability of FITC- labeled HPMA copolymer-ALN conjugate (P-ALN-FITC) and 
HPMA copolymer-D-Asp8 conjugate (P-D-Asp8-FITC) to hydroxyapatites with different 
crystallinity; black bars are high crystallinity and white bars exhibit low crystallinity. 













Figure 1.6. Initial uptake and localization of FITC- labeled HPMA copolymer-Asp8 
conjugate in bone compared with the uptake of tetracycline. (A) The conjugate 
preferentially incorporates in scalloped-appearing eroded surfaces in cancellous bone 
(white arrows); tetracycline (yellow label) is incorporated onto active bone mineralization 
surfaces. (B,C) Stained (B) and unstained (C) section of the same region of the proximal 
tibial growth plate and primary spongiosa. Tetracycline (yellow label) incorporated into 
the mineralizing zone of the growth plate (C, orange arrowhead) as expected, whereas 
HPMA copolymer-Asp8 conjugate (green label) localized in the resorption areas of the 
primary spongiosa (C, white arrows). Magnifications: A=150x; B,C=125x. Reprinted 






Figure 1.7.  Biodistribution in BALB/c mice of 125I-labeled HPMA copolymer-Asp8 
conjugates (P-Asp8) 24 h and 125I-labeled HPMA copolymer-ALN conjugates (P-ALN) 
48 h after i.v. administration. The impact of molecular weight and ALN content was 






Figure 1.8. Scheme of release of unmodified prostaglandin E1 (PGE1) from HPMA 
copolymer-Asp8-PGE1 conjugate.  Rate controlling cathepsin K cleavage is followed by 
































































































Figure 1.9.  General pathways affecting bone anabolism and cross-talk between 
osteoclasts and osteoblasts.  Most notably, PGE levels affect BMP-2 levels and vice 
versa, however, each contributes to bone anabolism by independent signaling pathways.  
Statins upregulate both BMP-2 and PGE through independent pathways. PGE and PTH1-
34 upregulate cAMP however, stimulation of EP2 or EP4 by PGE will also trigger 
MAPK cascades.  Not shown, PTH1-34 affects calcium levels in the body by regulating 
resorption in the kidneys and intestine.  Wnt plays a critical role in bone turnover by 
production of osteoprotegerin and therefore inhibition of RANKL-RANK interactions.  
Also of note, COX-2 represents basic components PGE production rather than 









Figure 1.10. Treatment of mCherry-labeled MG-63-Ras osteosarcoma tumor-bearing 
mice with free ALN and TNP-470, HPMA copolymer-ALN-TNP-470 conjugate, or 
vehicle alone.  (A) Structure of the HPMA copolymer-ALN-TNP-470 conjugate. (B) 
Intravital non-invasive fluorescence imaging of the tumor. (C) Tumor volume of 
mCherry-labeled MG-63-Ras tumor-bearing mice treated with free ALN and TNP-470 
(open triangles), HPMA copolymer-ALN-TNP-470 conjugate (closed triangles), or 
vehicle alone (closed squares) [80]. 
 
 
NOTE: This chapter is adapted with permission from the following publication: Low, S. 
A; Yang, J.; Kopeček, J. Bone-Targeted Acid-Sensitive Doxorubicin Conjugate Micelles 












BONE-TARGETED ACID-SENSITIVE DOXORUBICIN CONJUGATE  




 Osteosarcoma is a cancer of the bone that primarily affects adolescents.  While 
improvements in treatment have increased the 5-year survival rate to 65%, it still lags 
behind overall cancer survival rates for that age group [1].  Furthermore, the metastatic or 
recurring disease 5-year survival rate is still at a meager 20% [2].  Current osteosarcoma 
therapies include surgical resection followed by chemotherapy regimens of doxorubicin 
(DOX), high-dose methotrexate with leucovorin rescue, cisplatin, and ifosfimide [3].  
However, therapeutic indexes of these drugs are limited by severe toxicities; DOX, for 
instance, has well-documented cardiotoxicity [4].  
 Several groups have attempted to reduce this cardiotoxicity and enhance 
pharmacokinetics via large-molecule conjugation or nanoparticle entrapment.  For 
example, Susa et al. increased intracellular drug accumulation by loading lipid-modified 
dextran nanoparticles with DOX, effectively overcoming multidrug resistance in vitro [5].  
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Other groups targeted drugs with molecules such as bisphosphonates and acidic 
oligopeptides, which have a strong affinity to bone [6].  Utilizing this targeting 
methodology, Salerno et al. demonstrated reduction in bone metastases in mouse 
metastatic breast cancer models [7].  Hrubý et al. have used bisphosphonate targeting 
ligands on linear HPMA copolymers containing DOX bound via pH-sensitive hydrazone 
bonds [8].  They demonstrated in vitro HAp binding as well as pH-dependent DOX 
release, due to the reduced pH associated with the interstitial space in some tumors.  
 In contrast to their small molecule counterparts, these delivery systems have 
enhanced antineoplastic properties by improving pharmacokinetics and reducing 
unwanted side effects.  Improvements, however, can be made in these complex systems, 
as entrapped drugs may have a potential for premature release, and those with covalently 
bound drug yield drug-to-polymer weight percentages below 10%.  Fundamentally, these 
are valid systems that exhibit the important elements of having a bone-targeting ligand, 
drug, degradable linker, and large molecules with favorable pharmacokinetics.   
 Conjugating a targeting ligand modeled after bone sialoprotein, such as an aspartic 
acid oligopeptide to DOX via a hydrazone bond, would yield a practical, simple drug that 
might improve drug accumulation in bone [6].  However, it would lack the 
pharmacokinetics that are associated with larger molecules [9,10].  A modest design 
modification can change this.  DOX is a hydrophobic drug, but more importantly it has 
the tendency towards π-π stacking [11].  Furthermore, the aspartic acid oligopeptide-
targeting moiety is very hydrophilic.  By inserting aliphatic hydrocarbon chains and a 
flexible miniPEG spacer between DOX and the aspartic acid octapeptide, a novel 
micelle-forming unimer could be assembled (Figure 2.1).  This design exhibits high drug 
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loading while retaining covalent bonds between the targeting ligand and the drug.  The 
micellar self-assembly increases the size of the targeted delivery system, extending 
circulation and exposure to the tumor by reducing glomerular filtration.  Additionally, the 
sequestration of DOX to the center of the micelle is designed to reduce metabolism by 
the myocardium and thus reduce cardiotoxicity.  
 In order to test the viability of the proposed micellar delivery system as well as the 
relationship between structure and properties, four novel DOX-containing unimers with 
varying hydrophobicity as well as architecture have been synthesized.  Each unimer has 
been analyzed on its ability to form micelles, size, and adsorb to hydroxyapatite.  In 
addition, drug release and in vitro osteosarcoma toxicity have been analyzed.  
 
2.2 Experimental procedures 
2.2.1 Materials 
 Solvents, dimethyl formamide (DMF), dichloromethane (DCM), methanol (MeOH), 
dimethyl sulfoxide (DMSO), ethyl acetate, ether, and acetonitrile (ACN) were purchased 
from VWR, Fisher Scientific or Sigma-Aldrich, and were reagent grade or better.  
Piperidine, diisopropyl ethylamine (DIPEA), trifluoroacetic acid (TFA), triisoproyl silane 
(TIS), 11-aminoundecanoic acid (AUA), hydrazine, sodium carbonate (Na2CO3), and 
Dulbecco’s Modified Eagle Medium F-12 (DMEM) were purchased from Sigma-Aldrich.  
Magnesium sulfate and sodium sulfate were purchased from Fisher Scientific and 
Macron Chemicals, respectively.  1-(9-fluorenyl)methylchloroformate (Fmoc-Cl), Fmoc 
N-hydroxysuccinimide ester (Fmoc-OSu), and 2-[4-(2-hydroxyethyl)piperazin-1-




b]pyridinium 3-oxid hexafluorophosphate (HATU), and N-9-fuorenylmethoxycarbonyl-
D-aspartic acid (Fmoc-D-Asp-OH) were purchased from P3Biosystems.  
Diisopropylcarbodiimide (DIC) was purchased from Research Chemicals.  N-2-N-6-bis-
(9-fluorenylmethyloxycarbonyl)-L-lysine (Fmoc-Lys(Fmoc)-OH) was purchased from 
Aapptec and 9-fluorenylmethoxycarbonyl-8-amino-3,6-dioxaoctanoic acid (Fmoc-
miniPEG) was purchased from BioBlocks.  CAPTAL S hydroxyapatite (HAp) was 
purchased from Plasma Biotal LTD.  Holy carbon grids were purchased from Electron 
Microscopy Sciences. Sephadex LH20 beads were purchased from Amersham Pharmacia 
Biotech AM. Doxorubicin (DOX) was a generous gift from Meiji Seika Kaisha, Tokyo, 
Japan. Human osteosarcoma Saos-2 cells were purchased from ATTC.  2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt 




 (9-fluorenylmethyl carbazate).  Fmoc-hydrazine was synthesized as previously 
described [12] with modifications.  Briefly, 1 g Fmoc-Cl was dissolved in 20 mL of 
precooled ether, and this solution was added dropwise to 5x excess hydrazine suspension 
in ether in 1 h, immediately producing a white precipitate.  The reaction was stirred 
overnight and then added to 200 mL ethyl acetate under strong stirring.  Water was 
slowly added and the organic solution was washed twice.  The organic layer was 
transferred to a flask, and dried with anhydrous Na2SO4.  Removal of ethyl acetate was 




1H-NMR (DMSO-d6) δ 8.36 (s, 1H, CONH), 7.31-7.90 (m, 8H, Ar), 4.28 (m, 2H, 
CHCH2), 4.23 (m, 1H, CHCH2), 4.12 (br, s, 2H, NH2) 
 
2.2.3 Fmoc-11-aminoundecanoic acid 
 (11-(9-fluorenylmethoxycarbonylamino)undecanoic acid)) (Fmoc-AUA) was 
synthesized as previously described [13] with slight modification.  11-Aminoundecanoic 
acid (1 g, 5 mmol) was suspended in 50 mL of H2O-dioxane (v/v 4:1).  The pH of the 
suspension was adjusted to 9 using 10% Na2CO3.  After the mixture became clear 
solution under reflux, Fmoc N-hydroxysuccinimide ester (Fmoc-OSu; 1.68 g, 5 mmol) in 
dioxane (50 mL) was added dropwise over 20 min.  The reflux was kept overnight.  Then 
the cloudy mixture was diluted with H2O and acidified with 1 N HCl to pH 3.  
Dichloromethane (2 × 200 mL) was added to extract the product.  The organic phase was 
washed with brine twice, dried with anhydrous magnesium sulfate, and then concentrated 
by rotary evaporation under reduced pressure.  A white powder (1.83 g) was obtained 
with yield 86%; mp 127.8-128.5 °C. 
1H-NMR (DMSO-d6) δ 7.30-7.90 (m, 8H, Ar), 7.25 (t, 1H, CONH), 4.28 (m, 2H, 
CHCH2), 4.18 (m, 1H, CHCH2), 2.95 (m, 2H, NHCH2), 2.17 (m, 2H, CH2CO), 1.47 (2H, 
NHCH2CH2). 1.38 (2H, CH2CH2CO), 1.24 (12H, (CH2)6) 
 
2.2.4 Solid phase peptide synthesis 
  Synthesis of unimers was performed by standard Fmoc solid phase peptide 
synthesis. 2-chlorotrityl chloride resin (1.11 mmol/g) was loaded with 0.4 mmol/g Fmoc-
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hydrazine in DCM (a small amount of DMF was added due to solubility) overnight.  A 4-
fold excess of DIPEA was added as a base.  The resin was then capped with a mixture of 
DCM:MeOH:DIPEA 17:2:1 (20 mL x 4), followed by washing three times with DCM 
and DMF, consecutively.  After removal of Fmoc-group with 20% (v/v) piperidine in 
DMF, a 2.5-fold excess of Fmoc-AUA was added using DIC/HOBt as coupling agents. 
The completion of each coupling step was verified by Kaiser test. To prepare branched 
unimers, Fmoc-Lys(Fmoc)-OH was added following AUA. The branched unimers have 4 
aspartic acids on each branch with a total of eight instead of eight consecutive aspartic 
acids on the linear unimers (Figure 2.2).  Upon completion the resin was washed with 
DMF, DCM, and MeOH and dried in a desiccator.  Unimers were then cleaved using 
95:2.5:2.5 TFA:TIS:H2O and precipitated in diethyl ether.  Precipitated product was dried 
and purified on a preparative HPLC column (Agilent Zorbax 300SB-C18) using water 
with 0.1% trifluoroacetic acid (TFA) as the aqueous phase and ACN with 0.1% TFA as 
the organic phase.  Purified fractions had their volume reduced under low-pressure 
rotoevaporation followed by freeze-drying.  Purity was confirmed using HPLC (see 
Supporting Information).  Molecular weight for each unimer was confirmed using 
positive mode MALDI-ToF mass spectrometry (see Supporting Information).  Linear 
unimers are abbreviated A1-D8 and A2-D8, indicating that they have eight consecutive 
aspartic acids (D8) and delineating whether they have one (A1) or two (A2) AUA 
moieties, respectively.  The branched unimers are labeled A2-K-D4 and A4-K-D4 
indicating their lysine branch (K) and the four consecutive aspartic acids (D4), as well as 
two (A2) or four (A4) AUAs, respectively.  Both linear and branched unimers contain 8-





2.2.5 Conjugation to DOX 
 Purified unimers were conjugated to DOX via hydrazone bond using a 1:2 unimer 
to DOX molar ratio.  Dry DMSO was added to the dry ingredients until the mixture fully 
dissolved and mixed freely (approximately 10 µL DMSO to 1 mg DOX/unimer).  The 
solution was mixed in the dark at room temperature for three days and the progression of 
the reaction was tracked by HPLC (data not shown).  Following the reaction, free DOX 
was removed using an LH20 column.  The DMSO reaction solution was diluted five fold 
in methanol and added to an LH20 column.  Methanol was used as an eluent and 
collected fractions were dried under nitrogen yielding DOX-A1-D8, DOX-A2-D8, DOX-
A1-K-D4, and DOX-A4-K-D4. The final DOX content in micelles was determined using 
UV-vis spectrophotometry by measuring the methanol solution absorbance at 495 nm. 
Purity was confirmed using HPLC (see Supporting Information).  
 
2.2.6 Dynamic light scattering (DLS) 
 Size, polydispersity, and critical micelle concentration (CMC) measurements were 
all taken using a Wyatt DynaPro™ Plate Reader II and analyzed using Dynamics 7 
software.  Each DOX-bound unimer was dissolved in 0.01 M HEPES, pH 7.4.  For CMC 
measurement, dilutions were made in triplicates from 5 mg/mL down to 0.01 µg/mL on 
96-well plates (NUNC optical bottom black polystyrene plates), final volumes per well 
being 200 µL.  Plates were then sealed and refrigerated overnight prior to running DLS at 
20°C.  For size/ polydispersity measurements, samples with concentration of 1 mg/mL 
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were selected to coincide with cryoEM measurements (see below). 
 
2.2.7 Cryo-electron microscopy (CryoEM) 
 CryoEM (FEI Tecnai 12) was used to confirm the size of the micelles as well as 
observe their shape.  Samples were prepared at room temperature at 1 mg/mL DOX-
bound unimers in 0.01 M HEPES.  The samples were then manually added to holey-
carbon coated copper grids.  A FEI Vitrobot then blotted and plunged the samples into 
liquid ethane.  The samples were transferred to liquid nitrogen until imaged. 
  
2.2.8 Hydroxyapatite adsorption assay 
 Hydroxyapatite (HAp) adsorption was assessed for each DOX-bound unimer.  HAp 
was added to microcentrifuge tubes (3 mg/50 µL HEPES vehicle) followed by 350 µL of 
60 µM DOX-bound unimer solution.  The centrifuge tube was then vortexed for the 
allotted time and centrifuged at 7000 RPM for 1 min.  The supernatant was measured at 
480 nm on a Cary 400Bio UV-Spectrophotometer.  Data points measured in triplicates 
included times 0, 15 s, 30 s, 1 min, and 2 min. 
 
2.2.9 DOX release kinetics 
 DOX release kinetics were measured using an Agilent 1100 HPLC with heated 
autosampler plate.  Samples were prepared in triplicate at 0.1 mg/mL DOX-bound unimer 
in pH 5.5 and 7.4 in 1 M HEPES solutions.  Samples were placed in the HPLC 
autosampler, which retained a temperature of 37°C over the course of the experiment.  
Samples were run at 0, 1, 2, 3, 5, 10, and 24 h.  pH-dependent DOX release was 
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measured using HPLC UV absorption and calculated using the following equation: 𝐹𝑟𝑒𝑒 𝐷𝑂𝑋(𝐹𝑟𝑒𝑒 𝐷𝑂𝑋 +𝑚𝑖𝑐𝑒𝑙𝑙𝑎𝑟 𝐷𝑂𝑋)  𝑥 100 
 
2.2.10 Cytotoxicity 
 Cytotoxicity of DOX-bound unimers and free DOX toward human osteosarcoma 
Saos-2 cells was assessed using the CCK-8 bioassay.  Saos-2 cells were maintained in 
DMEM/F12 medium supplemented with 10% fetal bovine serum.  Plates (CELLSTAR 
TC 96-well) were seeded at a cell density of 4,000 cells/well and were administered 
dilutions of each unimer in triplicates.  Concentrations administered reflected hydrazone- 
bound DOX content in each micelle and was confirmed using spectrophotometer 
measurements in MeOH.  Following a 72 h treatment with drug, cytotoxicity was 
measured using CCK-8 per manufacturers’ instructions.  Each assay was repeated 3 times, 
IC50 values were expressed as the mean ± S.E.M. of three experiments. The data were 
analyzed using one-way analysis of variance to compare more than two groups, with p-
values <0.05 considered to be significant. 
 
2.3 Results and discussion 
 Drug carriers are often employed to increase solubility of hydrophobic drugs as 
well as boost their pharmacokinetics.  In designing a new carrier effective against 
osteosarcoma, it is important to produce a molecule that has a defined structure, produces 
micelles with reproducible polydispersity, and is stable.  Rather than focusing on 
increasing solubility, we decided to utilize the hydrophobic nature of chemotherapeutics 
to stabilize a micellar delivery system.  The targeting moiety, D-aspartic acid octapeptide 
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(D-Asp8), was selected for its optimized targeting potential,[14] its stability toward 
protease degradation associated with D-peptides, as well as its hydrophilic nature [15,16]. 
The addition of 11-aminoundecanoic acid (AUA) resulted in increased hydrophobicity. 8-
Amino-3,6-dioxaoctanoic acid (miniPEG) was placed between the AUA and the D-Asp8 
for additional flexibility of the backbone. An acid-sensitive hydrazone bond was 
incorporated at the unimer’s C terminus to bind DOX, a model drug selected for its 
hydrophobic nature as well as an ability to π-π stack with itself [17,18].  As such the 
prototype unimer DOX-A1-D8 was formed (Figure 2.2).  
 Thermodynamic stability of micelles increases as the hydrophilic/lipophilic balance 
(HLB) is lowered, e.g., by increasing the weight percent of the hydrophobic moiety.17  In 
order to verify this theory regarding stability in our micelles, an additional AUA moiety 
was added to DOX-A1-D8 to form DOX-A2-D8.  Continually adding hydrophobic AUA 
to the micelle has its potential drawbacks; if the hydrophobic portions far exceed the 
hydrophilic portions in a linear unimer, the conical shape of a single unimer may be lost, 
and the risk of an inverse micelle or other undesirable structures increases.18  To 
counteract this effect, yet retain the ability to increase stability by adding hydrophobic 
moieties, a modification was needed.  Branched head groups will, in theory, increase the 
lateral area of the head group, thereby retaining the conical structure of the micelle.  
DOX-A2-K-D4 demonstrates a simple addition of this branched head group (when 
compared to DOX-A2-D8), while DOX-A4-K-D4 doubles the number of hydrophobic 





2.3.1 Assessment of micelle formation and hydrodynamic diameter  
via dynamic light scattering  
 Verification of unimer self-assembly was determined by DLS.  Scattered light count 
rates exponentially increase as nucleation and assembly of micelles occur.  Therefore, 
plotting the normalized light-scattering count rate (counts per second) vs. concentration 
(LOG-LOG) graph (Figure 2.3) made the point of nucleation of the micelles readily 
apparent.  Micelle thermodynamic stability increased as expected when the number of 
AUA moieties was increased from two to four: DOX-A2-K-D4 0.0027 mg/mL to DOX-
A4-K-D4 0.00036 mg/mL.  By contrast, very little difference in thermodynamic stability 
was observed between branched and nonbranched micelles DOX-A2-D8, 0.0035 mg/mL 
vs. DOX-A2-K-D4, 0.0027 mg/mL.  Of note, by comparing documented blood volume  
 (<100 mL/kg of mouse) with standard in vivo DOX dosages (3 mg/kg/dose), even the 
least stable micelle DOX-A1-D8 at 0.0053 mg/mL is expected to remain above its critical 
micelle concentration after dilution during dosing [19–21].  Likewise, the average patient  
receives 60-75 mg/m2 dose of DOX and would also be above the CMC of the micelles 
upon dosing.[22–26]  
 The architecture, branched vs. linear, had a profound effect on the size of the 
micelles.  The higher degree of conicality created as head groups are branched should 
reduce the diameter of the micelle [27].  Indeed, the diameters of both branched unimers, 
DOX-A2-K-D4 and DOX-A4-K-D4 were 28.4 nm and 28.0 nm, respectively, smaller 
than their linear counterparts, DOX-A1-D8, DOX-A2-D8, which were 53.3 nm and 50.4 




2.3.2 Cryo-electron microscopy (CryoEM) 
 In addition to DLS, the size of the micelles was confirmed via CryoEM.  The shape 
was regular and spherical (Figure 2.5).  One anomaly that was observed in both DLS and 
CryoEM, however, was the surprisingly large size of the micelles.  Each unimer length is 
far shorter than the radius of an individual micelle.  Due to the discrepancy in expected 
size vs. what was experimentally observed, the self-assembly into a liposomal structure 
rather than a micelle was hypothesized. Further analysis of the cryoEM images did not 
reveal an evident bilayer; thus we believe that the structures are still micelles.  Also of 
note, the overall size of the micelles is above the renal threshold, but the size of the 
unimers is under the renal threshold.  Although blood vessel shear forces and protein-
micelle interactions drastically complicate predictions, it is feasible that under ideal 
conditions micelles could circulate above their critical micelle concentration; their size, 
above the renal threshold, could extend circulation time [28,29].  Over time, the micelles 
could extravasate from the blood stream as they bind to the bone at the tumor site, and 
eventually the blood concentration would dip below the critical micelle concentration; 
micelles then destabilize into unimers, which are readily cleared, as is the covalently 
bound DOX.  
 
2.3.3 HAp binding 
 Bone is a complex weave of organic fibers and inorganic mineral, giving it both 
rigidity as well as some elasticity.  The inorganic portion, hydroxyapatite HAp, 
composed of Ca10(PO4)6(OH)2, increases in crystallinity over time.  It is this higher 
crystalline state that aspartic acid oligopeptides (AO) preferentially bind to [30,31].  In 
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osteosarcoma patients, highly active osteoclasts produce extensive resorption surfaces by 
exposing highly crystalline HAp surfaces to which AO is able to target [32,33].  This 
specificity of AO for highly crystalline HAp additionally may reduce nonspecific binding 
to the majority of the noncancerous bone. 
 In an attempt to simulate bone binding, a HAp binding assay was carried out.  A 
low ratio of HAp to unimers was selected where saturation of the HAp occurred and an 
excess of all four unimers was present in measurable amounts, demonstrating the 
difference in binding between the four micelles.  Slight increases in HAp concentration 
yielded complete binding nearly immediately, reducing the discrepancy between each of 
the micelles (data not shown).  Still, each micelle reached their respective binding 
maximum (Bmax) nearly immediately, as previously noted [8,28].   Differences were 
observed in the amount of unimer needed to saturate the given HAp, although the rate of 
binding was nearly identical.  A general trend of lower saturation levels was observed for 
larger molecules.  The largest unimer, DOX-A4-K-D4, reached Bmax at 55±3.0%, 
whereas the lowest MW unimer, DOX-A1-D8, reached Bmax at 91±3.1% (Figure 2.6). 
This phenomenon may be due to steric hindrance [34].  An alternative explanation is that, 
due to the high surface energy of HAp, more hydrophobic molecules have reduced 
binding [35].  This hypothesis is unlikely as it would predict that slight variations in HAp 
concentration would have little affect on Bmax.  There was very little difference between 
branched and linear unimers of close molecular weights, DOX-A2-D8 and DOX-A2-K-





2.3.4 Release kinetics 
 Osteosarcoma provides a unique microenvironment, which can be exploited by a 
pH-sensitive hydrazone bond.  The hydrazone bond is stable at pH 7.4 but labile at acidic 
pHs. Therefore it would be cleaved in endosomal compartments (assuming cell 
internalization) [9].  Supposing strong adsorption of micelles with HAp occurs, an 
osteoclast-assisted release mechanism in the interstitial space is hypothesized.  
Osteoclasts, as stated previously, are highly active in osteosarcoma. The micelles that 
preferentially bind to resorption surfaces will be covered by osteoclasts.  The osteoclasts 
then produce a sealing zone or strong bond to the bone.  A resorption lacuna will be 
formed underneath the osteoclasts as these osteoclasts release cathepsin K, degrading the 
collagen fiber network, as well as protons, reducing the pH and degrading the HAp [36].  
The reduced pH could cleave hydrazone bond and release the DOX from the unimers.  
Incidentally, other bone metastases also recruit osteoclasts.  In turn, the osteoclasts, 
during resorption, release essential growth factors trapped in bone [37].  These micelles 
utilize osteoclast-assisted release, and therefore might have the potential to treat bone 
metastases. 
 Though lacunae have a pH of around 4-4.5, other groups measure hydrazone release 
kinetics at pH of 5.5, mimicking conditions in an endosome [38,39].  By using a pH of 
5.5 for our studies we are able to compare to what others have observed while gaining 
insight to what we might expect with lacunae release.  Trends in release seem to mirror 
the micellar thermodynamic stability established in the CMC experiments.  As stability of 
micelles increases, the rate of DOX release decreases (Figure 2.7). 
 We see a sigmoidal curve that may indicate a certain degree of destabilization is 
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necessary in order to achieve rapid release.  Ultimately, pH 5.5 release kinetics falls in 
the normal range of what is observed in literature [8,9,40,41].  However, at pH 7.4 we 
observed no detectable release, which appears to be slightly lower than what others have 
reported [8,9,40,41]. 
 A lower-than-expected release of DOX from DOX-A4-K-D4 micelles was observed.  
This is most probably connected to increased thermodynamic stability of the micelles. 
We hypothesize that more thermodynamically stable secondary packing is responsible for 
the low release rate of DOX from DOX-A4-K-D4 micelles. Before self-assembly into 
micelles, the unimers were eluted at higher elution time (12.5 min), indicating 
hydrophobic character.  However, after extended Incubation (48 h, 37°C) the peak moved 
to 3.6 min, indicating a very hydrophilic molecule, such as an intact micelle.  Release 




 IC50 values of DOX-containing micelles were determined and correlated with the 
drug release data.  Free DOX had a lower IC50 value 0.077± 0.009 µM than the micelles 
(p<0.01) (Figure 2.8).  Three of the micelles (DOX-A1-D8 0.39± 0.012 µM, DOX-A2-
D8 0.39± 0.021 µM, and DOX-A4-K-D4 0.45± 0.026 µM) did not differ significantly 
from each other (p>0.05).  However DOX-A2-K-D4 consistently produced slightly 
higher mean IC50 values (0.61± 0.086 µM) than the linear micelles (p<0.05), it was not 
statistically different from DOX-A4-K-D4 (p>0.05), its most similar compound.  Both 
DOX-A2-K-D4 and DOX-A4-K-D4 demonstrated slower release kinetics that may have 
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reduced the IC50 slightly for the test.  Most importantly, each unimer delivered its 
payload and demonstrated that it is pharmacologically active and has potential for future 
in vivo studies.  DOX-A4-K-D4 ended up being the most interesting because it forms the 
most stable micelle and yet retains nearly all the activity of the others. In addition, the 
cytotoxicity of A1-D8 (control; unimer without DOX) was minimal (94±5.2% cell 
viability at 1,000 µM). 
 
2.4 Conclusions 
 The premise of this study was to design, characterize, and optimize unimers for the 
treatment of osteosarcoma.  Each unimer component has one or more purposes for being 
included.  Most importantly, the targeting ligand provided both hydrophilicity to the 
amphiphile as well as targeting to HAp.  The drug, being covalently bound to the unimers 
via hydrazone bond, provided hydrophobic stability in addition to its therapeutic 
properties.  DOX-A1-D8 is the simplest unimer containing drug, degradable hydrazone 
bond, a single AUA, miniPEG, and a D-Asp8 targeting ligand.  By adding an additional 
AUA to DOX-A1-D8 we increased hydrophobicity (DOX-A2-D8) as well as the 
thermodynamic stability of the micelles.  Branched unimers incorporating longer 
hydrophobic chains were synthesized; DOX conjugates of branched unimers (DOX-A2-
K-D4 and DOX-A4-K-D4) possessed higher stability and smaller size of the micelles 
when compared to linear architectures.  Each unimer maintained its affinity to 
hydroxyapatite adsorption when in a micellar assembly.  In addition, at reduced pH (5.5) 
the hydrazone bond hydrolyzed and released unaltered DOX.  The rate of DOX release 
can be extended by increasing the stability of the micelles.  Ultimately, each micelle was 
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able to release unmodified drug in vitro.    
 Future studies may benefit from several of the micelle’s characteristics.  The sizes 
of the assembled micelles are above the renal threshold and we expect to see increased 
circulation and improved pharmacokinetics as compared to a targeted small molecule.  
Other key aspects of this delivery system include its potential for diverse applications.  
For example, this construct might be used to target a variety of bone maladies with other 
hydrophobic drugs that contain ketone or aldehyde groups in their structures.  Additional 
imaging moieties may be introduced and co-assembled into micelles, providing location 
and biodistribution information about the drug delivery system. 
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Figure 2.1. Illustration of micelle formation from amphiphilic unimer consisting of D-
aspartic acid octapeptide (D-Asp8), miniPEG spacer, hydrophobic tail based on 11-















Figure 2.3. Determination of the critical micellar concentration (CMC) of DOX-
containing unimers. A logarithmic plot of the intensity ratio in counts per second (CPS) 
vs. the logarithm of the unimer concentration.  The figure demonstrates the increased 












Figure 2.4. Size distribution of micelles as determined by dynamic light scattering in 0.01 
M HEPES (pH 7.4; 1 mg·mL-1).  A clear division between linear and branched unimers 










Figure 2.5. TEM image of micelles in 0.01M HEPES (1 mg·mL-1) at room temperature.  
The images confirm the sizes observed in the DLS studies as well as demonstrate the 











Figure 2.6. In vitro adsorption of DOX-containing micelles (52.5 µM) to HAp at 















Figure 2.7. In vitro release profiles of DOX from DOX-containing micelles (at pH 5.5 
and pH 7.4 at 37 oC) measured by HPLC. Of note, all of the pH 7.4 data are on the 






















Figure 2.8. Cytotoxicity of free DOX and micelles with variable structure towards human 
osteosarcoma Saos-2 cells following 72 h incubation. 
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Healthy bone is a mix of 50-70% mineral, 20-40% organic matrix, 5-10% water, 
and 1-5% lipids and is constantly being recycled into new bone in order to maintain its 
rigidity and flexibility [1–3].  At the beginning of this recycling process, monocytes 
receive several signals, pushing them to differentiate into osteoclasts.  Osteoblasts then 
express Receptor Activator of Nuclear Factor κ B Ligand (RANKL) to the Receptor 
Activator of Nuclear Factor κ B (RANK) surface receptor in monocytes, initiating the 
TRAF6 cascade, committing the monocytes to osteoclastogenesis.[4,5] Mature 
osteoclasts then initiate healthy catabolic bone resorption.  Anabolic processes begin as 
mesenchymal stem cells (MSCs) are stimulated to become osteoblasts by the BMP-
2/Runx2 and Wnt/β-catenin pathways.  Matured osteoblasts then deposit osteoid, a 
component of the bone matrix primarily composed of type I collagen, which mineralizes 
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and becomes new bone [6,7]. 
A narrow balance of catabolism or anabolism is responsible for healthy bone.  
Alteration of this balance results in diseased bone.  Osteoporosis occurs when catabolism 
surpasses anabolism wherein a two-standard deviation decrease in bone density from 
healthy bone is observed.  In the US, approximately 44 million people have low bone 
density, and 10 million people suffer from osteoporosis.  By 2020, an estimated 61 
million are projected to have osteoporosis [8].  In general, osteoporosis can be treated 
with a regimen of bisphosphonates, which inhibits osteoclasts, thereby slowing 
catabolism and healthy bone turnover.  This becomes problematic when bone fractures 
occur and proper bone turnover is retarded by bisphosphonates.  These complications 
include crippling vertebral and hip fractures with estimated costs between in $13.7 billion 
and $20.3 billion in 2005 [9].  
Clinical treatment of these fractures generally does not include site-specific 
anabolic drugs.  In fact, the only drugs approved for clinical use on fractures are BMP-2 
and BMP-7, which are applied locally for use in open long-bone fractures and spinal 
fusions [10].  However, the need for broader application of anabolic drugs to treat bone 
maladies such as osteoporotic fractures is evident when one considers that 85% of the use 
of anabolics are off-label [11].  Still, the FDA judiciously continues to limit approved use 
of locally administered drugs to fractures that are already open and at risk of infection.  
This limitation necessitates a clinically relevant approach to treating these fractures: a 
fracture treatment drug that is administered systemically yet targets the fracture site. 
Efficacy in targeting fractures in humans has been demonstrated for quite some 
time, as radiolabeled methylene diphosphate and hydroxymethylene diphosphate are used 
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to diagnose hairline fractures.  The use of bisphosphonates as fracture-targeting ligands 
inhibits both osteoclasts and angiogenesis, returning to the original problem of retarding 
bone turnover, which is critical for fracture healing [12–14].  Nature has a more 
biocompatible answer.  Sialoprotein is one of several naturally occuring proteins that 
display a strong affinity for hydroxyapatite (HAp), a mineral found in bone.  Several 
strings of acidic amino acids are responsible for sialoprotein’s bone affinity.  Modeled 
after sialoprotein, a biocompatible targeting ligand can be produced by combining a 
string of eight aspartic acids [15].  The aspartic acid octapeptide prefers the crystalline 
state of HAp, which is exposed at the time of a fracture [3,16].  Our previous studies 
involving aspartic acid octapeptide targeted doxorubicin containing micelles for the 
treatment of osteosarcoma demonstrated that after conjugation to a drug and self-
assembly into a micelle, the aspartic acid retains its HAp binding abilities [17].  
Having a bone-targeted peptide that targets fractures locally means that it is 
important to select a drug which acts locally to stimulate bone growth.  Of particular 
interest in this area are GSK3β inhibitors.  GSK3β is an enzyme that can degrade beta-
catenin and thus impact the Wnt/catenin pathway.  Inhibition of GSK3β, therefore, 
promotes a robust osteoblast population and aggressive bone anabolism, as several 
groups have shown [18].  Chen et al. demonstrated that levels of β-catenin in fractures far 
exceed those of healthy bone.  By using a β-catenin knockout transgenic mouse model, 
fracture healing is essentially stopped with the removal of β-catenin.  More importantly, 
they demonstrated that the addition of lithium chloride, a basic GSK3β inhibitor, to the 
mouse diet increased the bone density of the fracture callus [19].  Sisask et al. 
demonstrated that a much more potent GSK3β inhibitor administered orally increased 
		
94	
load failure of fractured femurs by 270% compared to the vehicle alone [20].  Toxicity 
profiles of GSK3β inhibitors in these studies are low enough for oral administration of 
the drug; however, the targets of GSK3β, Wnt and Hedgehog signaling, are pathways 
found in many cell types and tissues, and one must be cautious of both short-term and 
long-term side effects.  The potential off-target effects of GSK3β inhibitors as well as 
their high potency and large therapeutic window make them excellent candidates for a 
targeted therapeutic.  We have selected 6-bromoindirubin-3'-oxime (6Bio), a potent 
GSK3β inhibitor with an enzymatic IC50 of 5 nmol because of its proven track record 
growing bone [18,21].  
Conjugating the targeting ligand aspartic acid oligopeptide to 6BIO via a 
hydrolyzable oxime ester bond would yield a simple drug that would likely improve drug 
accumulation in bone.  However, with slight modifications it is possible to target the site 
of inflammation in addition to the bone [22,23].  6BIO is a drug that is hydrophobic, 
while the aspartic acid oligopeptide-targeting moiety is very hydrophilic.  Upon addition 
of aliphatic hydrocarbon chain between 6BIO and the aspartic acid chain a micelle 
unimer is formed (Figure 3.1).  The micelle increases the overall size of the drug carrier, 
thereby increasing uptake in the inflamed tissue.  Unlike traditional micelles, however, 
each unimer contains a targeting ligand as well as a drug, ensuring high drug loading.  
Additionally, should the micelle destabilize in the blood stream, the drug will remain 






3.2 Experimental procedures 
3.2.1 Materials 
Solvents, dimethylformamide (DMF), dichloromethane (DCM), methanol (MeOH), 
dimethyl sulfoxide (DMSO), ethyl acetate, ether, and acetonitrile (ACN) were purchased 
from VWR, Fisher Scientific, or Sigma-Aldrich and were reagent grade or better.  
Piperidine, diisopropyl ethylamine (DIPEA), trifluoroacetic acid (TFA), triisopropyl 
silane (TIS), lithium hydroxide, bis(benzonitrile)palladium(II) chloride, copper(I) 
bromide, ethylenebis(diphenylphosphine) (DPPE), Chloramine T trihydrate, lithium 
diisopropyl amide (LDA), propargyl chloride, and sodium carbonate (Na2CO3), were 
purchased from Sigma-Aldrich.  Sodium sulfate was purchased from Macron Chemicals.  
Fmoc-11-aminoundecanoic acid (Fmoc-AUA), 1-[bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]-pyridinium 3-oxide hexafluorophosphate (HATU), chloro-trityl 
resin, and N-9-fuorenylmethoxycarbonyl-L-aspartic acid (Fmoc-L-Asp-OH) were 
purchased from AKsci.  N-2-N-6-Bis(9-fluorenyl-methyloxycarbonyl)-L-lysine (Fmoc-
Lys(Fmoc)-OH) was purchased from Aapptec and 9-fluorenylmethoxycarbonyl-8-amino-
3,6-dioxaoctanoic acid (Fmoc-miniPEG) was purchased from BioBlocks.  Sephadex 
LH20 beads were purchased from Amersham Pharmacia Biotech AM.  Fmoc–
Azidohomoalanine (Fmoc-Dab(N3)-OH), 3-acetoxylindole, and Bromostatin were 
purchased from Chem-Impex International.  
 
3.2.2 Synthesis of 6’-bromoindirubin (I) 
6’-Bromoindirubin was synthesized as previously described [24] with 
modifications.  Briefly, 615 mL of anhydrous methanol was set stirring under nitrogen in 
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a 2 L round bottom flask.  6-Bromoisatin 3.37 g (15 mmol) and 3-acetoxylindole 2.63 g 
(15 mmol) were then added and the solution was bubbled with nitrogen for 45 min.  
Anhydrous sodium carbonate 3.98 g (37.5 mmol) was added and the reaction was stirred 
for 5 h in the dark.  The resultant dark purple precipitate was isolated by centrifugation, 
the solid decanted with methanol and resuspended in ethyl acetate. The 6’-
bromoindirubin was washed 3x with brine.  The organic layer was dried with sodium 
sulfate and the solvent removed under reduced pressure to yield a dark purple solid.  
Yield: >90%, mass: 338.94, 340.93 (the two masses are due to the two common isotopes 
of bromine). 
 
3.2.3 Synthesis of 6’-bromoindirubin-3’-oxime  
(II, 6BIO). 6′-bromoindirubin-3′-oxime  (6BIO) was synthesized as described in 
Polychronopoulos et al. [24].  6-Bromoindirubin 3.06 g (9 mmol) and hydroxylamine 
hydrochloride 6.25g (90 mmol) were combined in a pressure reaction tube.  Ninety mL of 
pyridine was added and purged under argon for 30 min.  The reaction was sealed and 
stirred at 115-120° C for 2.5 h.  The pyridine was removed under reduced pressure and 
the dark red product solid was washed with hexanes.  The product was suspended in ethyl 
acetate and washed 2x with water followed by a wash with brine.  The organic phase was 
dried with sodium sulfate and solvent removed under reduced pressure yielding a dark 






3.2.4 Synthesis of 2,2-dimethylpent-4-ynoic acid 
Briefly, a round-bottom flask was dried and purged with nitrogen and cooled to -
78°C.  LDA 2M 6.1 mL (13 mmol) was added and a stream of nitrogen was used to 
bubble the reaction.  Methyl isobutyrate 1.6 mL (14 mmol) was added dropwise as the 
reaction was stirred.  Propargyl chloride 891 µL (10 mmol) was also added dropwise as 
the reaction was stirred vigorously.  The solution was allowed to warm to room 
temperature and was stirred over night.  The reaction was then quenched with 
concentrated NH4Cl and extracted with ethyl acetate.  The organic layer was dried with 
sodium sulfate and solvent removed under reduced pressure until a yellow oil remained.   
Lithium hydroxide 480 mg (20 mmol) and MeOH were added to the product and 
stirred overnight, removing the methyl ester.  Water was added to the reaction and 
acidified to pH 2 prior to extracting twice with ethyl acetate.  The organic layer was dried 
with sodium sulfate and the solvent was removed under reduced pressure.  Yield was 7% 
(2,2-dimethylpent-4-ynoic acid). 
 
3.2.5 Synthesis of (2Z,3E)-6'-bromo-3-(((2,2-dimethylpent-4-ynoyl)oxy)imino)-
[2,3'-biindolinylidene]-2'-one (III) 
6BIO was conjugated to 2,2-dimethylpent-4-ynoic acid using standard DCC-
assisted ester coupling.  6BIO 18 mg (0.05 mmol), 2,2-dimethylpent-4-ynoic acid (7.5 
mg; 0.06 mmol), and DCC 12.4 mg (0.06 mmol) were added to 3 mL of DMF under 
nitrogen.  DIPEA 26 µL (0.15 mmol) was then added and the reaction was stirred under 
nitrogen for 4 h.  The product was filtered and dissolved in ethyl acetate.  The solution 
was then washed 3 times with water and dried with sodium sulfate.  The solvent was 
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removed under reduced pressure onto celite (diatomite) and purified using flash 
chromatography (hexanes / ethyl acetate) (see Supporting Information).  Yield: 80%. 
 
3.2.6 Synthesis of amphiphilic unimers flanked with C-terminal azide 
Unimers were synthesized as previously described with slight modifications [17].  
Briefly, in a small glass vial, 2-chlorotrityl resin (1.11 mmol/g)  was loaded at 0.4 
mmol/g with Fmoc-Dab(N3)-OH overnight in DCM and DIPEA.  The resin was 
transferred to a SPPS vessel capable of bubbling nitrogen.  The resin was then capped 
with four 5 mL washes of DCM:MeOH:DIPEA (17:2:1) followed by three washes of 
DMF.  Following each amino acid addition, Fmoc-groups were removed during two 20-
min incubations with 20% (v/v) piperidine in DMF.  The resin was then washed three 
times with DMF prior to the next amino acid being added.  Fmoc-AUA was added twice 
in a five-fold excess using HATU/DIPEA.  Following addition of Fmoc-AUA, branched 
unimers (N3-A2-K-D4) were prepared by adding Fmoc-Lys(Fmoc)-OH followed by 
miniPEG and 4 aspartic acids.  Linear unimers were created by adding miniPEG and 8 
aspartic acids to the AUA.  Both unimers were capped with acetic acid, HATU, and 
DIPEA.  The final resin-bound products were washed with DMF, DCM, MeOH (3 x 
each) and dried under nitrogen.  The products were cleaved from resin using 







3.2.7 Click conjugation of (2Z, 3E)-6'-bromo-3-(((2,2-dimethylpent-4-
ynoyl)oxy)imino)-[2,3'-biindolinylidene]-2'-one to unimers 
 N3-A2-D8 and N3-A2-K-D4 (both 0.01 mmol) were dissolved in DMF and purged 
with nitrogen for 20 min.  Additional DMF was purged with nitrogen and was used to 
dissolve a mixture of (2Z,3E)-6'-bromo-3-(((2,2-dimethylpent-4-ynoyl)oxy)imino)-[2,3'-
biindolinylidene]-2'-one (0.03 mmol), copper(I)bromide (0.01 mmol), and TBTA (0.01 
mmol).  The two solutions were combined and stirred under nitrogen for 20 min.  
Ascorbic acid (0.01 mmol) and a drop of water were then added.  The reaction proceeded 
for 40 min, after which it was diluted in MeOH and purified on LH20 column.  The 
fractionated peaks were dried under reduced pressure.  Yields for BIO-N3-A2-D8 and 
BIO-N3-A2-K-D8 were 65% and 48%, respectively (see Supporting Information).  
 
3.2.8 Dynamic light scattering measurements of micelles 
The hydrodynamic radius of the micelles were determined using Malvern Zetasizer 
Nano ZS.  Measurements of both unimers were taken using 2.4 nmol/mL unimer at 25°C.  
Malvern software was used to determine hydrodynamic diameter.  
 
3.2.9 Release kinetics of 6BIO from micelles 
Release kinetics was measured for each of the micelles. Unimer (0.1 mg) was 
dissolved in 1 mL of PBS containing 30% MeOH.  Samples for each time point (0, 1 h, 2 
h, 4 h, 8 h, 12 h, and 24 h) were made in triplicate.  Each sample was incubated in a water 
bath at 37°C for the allotted length of time.  Each sample was then measured at λ=290 
nm on an Agilent 1200 (0.01 M NH4HCO3, ACN).  Area under the curve was measured 
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using MestReNova software and the percent of the drug peak released was calculated as 
follows: Free 6BIOFree 6BIO+Micellar 6BIO ∗ 100 
 
3.2.10 Stannylation of 6BIO 
Stannylation of 6BIO was performed as previously described for other indols [25].  
To a pressure tube, 6BIO (1 mmol) was dissolved in 20 mL dioxane and purged with 
argon for 30 min.  PdCl2(PhCN)2 (0.05 mmol), DPPE  (0.1 mmol), and tributyl tin (3 
mmol) were then added.  The tube was purged with argon for an additional 10 min and 
sealed.   The reaction was stirred vigorously at 110°C for 12 h.  The product was dried on 
celite and purified using flash chromatography (hexanes 1% TEA/ EtOAc).  The solvent 
was removed under reduced pressure resulting in a brown red solid (2Z,3E)-3-
(hydroxyimino)-6'-(tributylstannyl)-[2,3'-biindolinylidene]-2'-one (see Supporting 
Information). 
 
3.2.11 O-Alkylation of stannylated BIO ((2Z,3E)-3-(hydroxyimino)-6'-
(tributylstannyl)-[2,3'-biindolinylidene]-2'-one) 
DMF was added to a mixture of (2Z,3E)-3-(hydroxyimino)-6'-(tributylstannyl)-
[2,3'-biindolinylidene]-2'-one (56 mg; 0.1 mmol), propargyl chloride (7.2 µL; 0.1 mmol), 
and cesium carbonate 38 mg (0.1 mmol) and stirred vigorusly [26].  The reaction was 
monitored every half hour throughout the reaction by LC/MS.  At 1.5 h a small amount of 
dialkylated side-product was formed, and the reaction was stopped by adding water.  The 
product was then extracted into EtOAc and washed 3 times with water and dried on 
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sodium sulfate.  Celite was added and the solvent was removed by reduced pressure.  The 
product was purified by reverse phase chromatography (H2O-1% DIPEA; ACN-1% 
DIPEA).  The product, (2Z,3E)-3-((prop-2-yn-1-yloxy)imino)-6'-(tributylstannyl)-[2,3'-
biindolinylidene]-2'-one, was brownish purple (see Supporting Information). 
 
3.2.12 Conjugation of alkylated stannylated 6BIO to unimers 
Each unimer (N3-A2-D8 or N3-A2-K-D4)  (0.01 mmol) was dissolved in DMF and 
purged with nitrogen for 20 min.  To a separate vial of DMF purged with nitrogen  
(2Z,3E)-3-((prop-2-yn-1-yloxy)imino)-6'-(tributylstannyl)-[2,3'-biindolinylidene]-2'-one 
(0.03 mmol), copper(I)bromide (0.01 mmol), DIPEA (0.1 mmol), and TBTA (0.01 
mmol) were added.  The two solutions were combined and stirred under nitrogen for 40 
min. Upon completion the reaction was diluted in MeOH and purified on LH20 column 
(MeOH 1% DIPEA). The fractionated peaks were dried under reduced pressure, yielding 
a bluish purple solid. 
 
3.2.13 Radio-iodination of micelles and 6BIO 
The stannylated unimers and stannylated 6BIO (0.3–0.5 µmol) were dissolved in 
100 µL DMF. The solutions were transferred to Wheaton V-vials containing a solution of 
[125I]NaI (5.0 mCi) in 100 µL DMF phosphate-buffered saline (PBS) (pH 7.4). 
Chloramine-T was added, and the reaction mixture stirred for 15 min at ambient 
temperature.  Purification of the iodinated micelles was performed using a LH20 column 
eluted with MeOH.  Iodinated 6BIO was dissolved in EtOAc and was washed twice with 
water.  The solvent of all three reactions was evaporated using a stream of nitrogen, and 
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the residue was dissolved with PBS (pH 7.4) to obtain solutions with an activity 
concentration of 370 kBq/100 µL. The overall radiochemical yield was ca. 10% (see 
Supporting Information). 
 
3.2.14 Murine fracture induction 
All animal studies were reviewed and approved by Purdue’s animal care and use 
committee protocol and were performed as described in the literature.  CD4 Swiss mice 
(30-35 g) acquired from Harlan laboratories were used for these experiments.  A 
stabilized femoral fracture was performed under aseptic conditions with isoflurane 
anesthesia.  Skin around the knee was shaved and cleaned with an alcohol pad first, then 
with Betadine solution.  The skin incision was made medial parapetellar.  The patella was 
then dislocated and an incision was made under the patella.  A 25 gauge needle was used 
to ream the intramedullary canal.  A 22-guage locking nail (where both ends are flattened 
to produce rotational stability), was then inserted.  The wound was sutured and the bone 
was then fractured using a three point bending device that has a built-in stop to prevent 
excess injury.   Subcutaneous Buprenorphine (0.05 – 0.1 mg/kg) was administered at the 
time of surgery, followed by a dose every 12 h for 3-7 days post operation. 
 
3.2.15 Injection and dissection techniques/counting for 24 h biodistribution 
From the iodinated products described previously 1 uCi/mL solutions were made in 
sterile PBS.  The study was performed on 3 groups of mice with 5 mice per group.  Two 
weeks following fracture induction, each mouse received a 0.1 µCi (0.1 mL) dose of the 
radio-iodinated linear micelles, branched micelle, or free drug.  Animals were then placed 
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back in their cages for 24 h.  At 24 h they were euthanized using CO2 excess.  Blood was 
drawn from a cardiopuncture and all other organs measured were removed (lungs, liver, 
spleen, kidneys, fractured femur, healthy femur).  The activity was counted using Packard 
Cobra Auto-Gamma and was normalized by dividing the count rate by the weights of 
each organ. 
 
3.2.16 Injection and techniques for imaging 
From the iodinated products described previously, 1 mCi/mL solutions were made 
in sterile PBS.  The study was performed on 3 groups of mice with 5 mice per group. 
Two weeks following fracture induction each mouse received 0.1 mCi (0.1 mL) of dose.  
Animals were then returned to their cages until euthanasia by CO2 overdose at the desired 
time point (1 h, 4 h, 24 h).  Animals were imaged using MiLabs U-SPECT-II/CT.  3D 
reconstructions were performed using Image J software. 
 
3.3 Results and discussion 
3.3.1 Design and characterization of micelles 
We set out to develop a fracture-targeted anabolic-loaded micelle by utilizing the 
unique microenvironment available in bone fractures.  That is, freshly exposed HAp due 
to a fracture, additional HAp exposed by osteoclasts during resorption, newly exposed 
calcified bone, and the local inflammatory response.    
HAp can be targeted using any one of several bone adsorbing ligands, including 
bisphosphonates, tetracycline, and acidic oligopeptides.  Both bisphosphonates and 
tetracycline have biocompatibility issues with osteonecrosis of the jaw and the staining of 
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teeth yellow, respectively [27–29].  In order to maintain bone homeostasis, the more 
biocompatible option is acidic oligopeptides.  Aspartic acid octapeptide, as evidence 
suggests, is near an ideal number of aspartic acids to ensure rapid binding [30].  Unlike 
bisphosphonates and tetracyclines, aspartic acid octapeptide has a low toxicity even in 
very high concentrations [17,31]. 
Targeting a drug to a fracture site via aspartic acid octapeptides by itself does not 
fully exploit the microenvironment of a fracture.  In fractured bones, the extent of bone 
accumulation is expected to be far more dramatic when using large molecules.  Yuan et 
al. proposed a mechanism by which inflamed tissue leads to leaky vasculature and 
subsequent inflammatory cell-mediated sequestration (ELVIS).  This theory essentially 
states that large molecules will readily be extravasated from the leaky vasculature of the 
inflamed fracture callus.  Then, inflammatory cells actively phagocytose and sequester 
any large molecules in the area [32,33].  Bone fracture calluses certainly fall under the 
category of inflamed tissue, and as such, higher drug accumulation could hypothetically 
be achieved by increasing the size of a drug delivery system.   
The proposed micellar design is a simplified way of increasing the size of the drug 
delivery system to increase accumulation in inflamed tissue.  By using the hydrophilic 
targeting peptide, aspartic acid octapeptide, covalently bound by a hydrolyzable linker to 
a hydrophobic drug, a micelle-forming unimer was created.  The designed unimer was 
largely synthesized using solid-phase peptide synthesis (SPPS).  Synthesis began with an 
azide-containing amino acid (azidohomoalanine) that provided a clickable point of 
attachment for a drug/linker.  To the azide-containing amino acid, two 11-
aminoundecanoic acids (AUAs) were attached to increase the hydrophobicity and 
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therefore the stability of the micelle.  A miniPEG spacer (8-amino-2,6-dioxaoctanoic 
acid) was added for flexibility, followed by aspartic acid octapeptide for targeting.  
Finally, the unimer was capped with acetic acid, preventing the terminal primary amine 
from initiating premature hydrolysis of the amine-sensitive drug linker yielding the 
finalized linear unimer, BIO-A2-D8 (Figure 3.2).  BIO-A2-D8 indicates that it is a 6BIO 
(BIO)-containing unimer with two aminoundecanoic acids (A2) and eight aspartic acids 
in a linear fashion (D8).   
The stability of the micelle can be modified by increasing or decreasing the number 
of AUAs.  However, increasing the number of AUAs in a linear micelle by too much can 
result in aggregates and nonmicellar structures.  To increase the number of AUAs and 
avoid the formation of nonmicellar structures, we also studied a branched aspartic acid 
head group.  Building from the original azide-aminoundacanoic acid base, lysine was 
added to the second aminoundecanoic acid.  Both primary amines on the lysine were 
deprotected and miniPEG was added to both, followed by four aspartic acids each and 
capping with acetic acid.  The 6BIO (BIO)-conjugated unimer containing two 
aminoundecanoic acids (A2) is branched at the lysine (K) and ends in two branches of 
four aspartic acids (D4), yielding BIO-A2-K-D4.  This branched conformation increased 
the head group size and therefore the conicity of the unimer.  By increasing the head 
group size, far greater hydrophobic portions could be incorporated before the conicity of 
the unimer was lost, and a bilayer, aggregate, or other conformation was formed [17].  
The designed micelles, in addition to increasing the fracture accumulation by 
increasing the size, have several unique features.  By building the unimers by SPPS, the 
unimers were monodisperse, which aided in characterization.  Furthermore, each unimer 
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featured a targeting ligand and a drug.  This means that in the event of the micelle 
rupturing in the blood stream, the drug still could accumulate in the fracture site by 
aspartic acid octapeptide-HAp interactions.  In addition, whereas many micelles have 
inconsistent drug loading, the linear and branched micelles contained a consistent 17% or 
15% drug loading by weight, respectively.  
The drug being attached to the unimers was a GSK3β inhibitor, 6BIO. It has been 
used for increasing osteoblast activity and has an enzymatic IC50 of 5 nmol [18,21,34].  
6BIO by itself, however, is not soluble in water.  By including 6BIO in the unimer 
design, the unimer solubilized the drug while the drug stabilized the micelle.  The oxime 
of 6BIO was first conjugated to the carboxylic group of a 4-pentynoic acid derivative and 
then clicked to the azide-containing unimer by the alkyne on the 4-pentynoic acid 
derivative.  Upon completion of the click reaction, the micelle was purified, dried, and 
formed micelles upon reconstitution in PBS. 
 
3.3.2 Size determination by dynamic light scattering 
Dynamic light scattering was used to determine the hydrodynamic diameter of the 
micelles.  The micelles self-assembled at the concentrations theorized to be sufficient for 
injection for fracture healing.  BIO-A2-D8 and BIO-A2-K-D4 were 28.8 nm and 11.2 
nm, respectively (Figure 3.3).  Sizes were slightly smaller than the micelles with similar 






3.3.3 Micellar drug release 
Drug-linker selection plays an important role in maintaining targeting ligand to drug 
integrity until the drug has reached the target tissue.  This micelle features an oxime 
linkage which is base sensitive and hydrolytically cleavable at the pH ranges found in a 
bone fractures (6.9-7.6) [35].  Simple 4-pentynoic oxime esters degrade within hours (see 
Supporting Information) and would likely release 6BIO prior to fracture accumulation.  
To improve the hydrolytic stability of the conjugate, germinal dimethyl substituents were 
introduced into the structure (Figure 3.2).  This increased steric hindrance to the 107° 
Bürgi-Dunitz angle required for a Bac2 reaction to release the drug and completely 
eliminate the possibility of an E1cb reaction.  The stabilized oxime ester linkage slowly 
reached 30% release over 24 h and continued to release over several days (Figure 3.4).  
Though the linker is not specific to the fracture microenvironment, the slow degradation 
would reduce the amount of drug released in the blood stream prior to fracture 
accumulation, and reduces the frequency of necessary dosing for treatment. 
 
3.3.4 Biodistribution 
3.3.4.1 Organ biodistribution at 24 h 
BIO-A2-D8 and BIO-A2-K-D4 have hydrolyzable oxime ester linkages designed to 
release the 6BIO for treatment of bone fractures.  Although a cleavable linker is 
necessary for therapy studies, it may pose a problem with biodistribution studies.  At 24 h 
of an in vivo study, 30% of the drug may be released.  In a biodistribution study, 
premature release would not give accurate information on how well the targeting ligand 
is able to remain in the fracture site.  A nondegradable oxime ether linker replaced the 
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oxime-ester linker in the micelles for biodistribution.  Radiolabeling BIO-A2-D8, BIO-
A2-K-D4 and 6BIO was done by substituting the bromine on 6BIO with 125I.  These 
minor modifications allowed the majority of the molecule to remain unmodified while 
giving information on targeting and free drug clearance (Figure 3.5).  
In bone, HAp increases in crystallinity over time.  It is this higher crystalline state 
to which AOs preferentially bind [3,16].  In bone fracture patients, highly active 
osteoclasts produce extensive resorption surfaces by exposing highly crystalline HAp 
surfaces to which AOs are able to target [36].  This specificity to highly crystalline HAp 
may additionally reduce nonspecific binding to the majority of the nonfractured bone.  
An organ biodistribution was performed to elucidate this and other questions about the 
fate of the micelles in vivo. 
Several interesting observations emerged from the biodistribution.  6BIO is a 
hydrophobic drug and its high accumulation in the lungs, liver, and spleen was likely due 
to the drug aggregating.  By turning the drug into an amphiphile, the particle size was 
controlled, and the liver, spleen, and lung accumulation all decreased significantly 
(p<0.001) (Figure 3.6).  However, kidney uptake dramatically increased with both 
micelles (p<0.001).  The kidney accumulation may be due to the kidney’s ability to 
recycle peptides such as the aspartic acid octapeptide back into the blood stream [37,38].  
As long as the micelle is not internalized into renal cells, the 6BIO should eventually 
hydrolyze, be cleared, and not inhibit GSK3β expression. 
The primary purposes of this study were to elucidate the bone- and fracture-
targeting potential of targeted micelles over free drug, as well as the differences between 
branched and linear designs.  Naturally, accumulation in healthy femurs was higher in 
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both the linear (1.0±0.27; p<0.01) and the branched (1.4±0.14; p<0.001) micelles than 
free 6BIO (0.5± 0.10).  This is also the first evidence of the branched micelle having a 
higher accumulation than the linear micelle in bone (p<0.05).  These trends were 
amplified when comparing the fractured femurs.  The fractured femurs of the free 6BIO, 
linear, and branched micelles were each statistically different from each other (p<0.001), 
with values of 0.4±0.05, 1.9±0.32, and 6.0±0.51, respectively.  Both unimers 
demonstrated an important increase of accumulation in the fractured femurs over the free 
drug control.   
The micelles were able to show fracture-specific targeting compared to healthy 
bone.  While there was no statistical difference in accumulation of the free drug between 
the healthy and the fractured femurs, both the linear and the branched micelles showed 
significantly (p<0.001) higher drug uptake in the fractured femur by a 1.8 and a 4.3 fold 
increase, respectively.  
 
3.3.4.2 SPECT/CT biodistribution 
In order to validate the organ biodistribution and study the clearance of the 
micelles, SPECT/CT imaging was performed at 1 h, 4 h, and 24 h (Figure 3.7).  In 
general, fracture-specific uptake was more evident at later time points than earlier ones.  
At 1 h, a small amount of fracture accumulation was visible in both micelles; however, 
high signal intensities in both the lungs and kidneys made them difficult to discern.  On 
the other hand, at 1 h, the free drug was primarily found in the stool.  At 4 h, free drug 
was still primarily contained in the bowel; however, spleen accumulation began to be 
more evident.  Again this bowel uptake was likely due to aggregation of free 6BIO and 
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the resultant uptake by macrophages in the lungs, liver, and spleen, resulting in clearance 
through the bile into the bowels.  Meanwhile, the linear micelle had cleared somewhat 
from the lungs, was still strong in the kidneys, but much more visible in the fracture.  The 
branched unimer showed superior targeting at 4 h, with the majority of accumulation in 
the femur and kidneys.  At 24 h, free drug appears to be cleared; all signals were 
background.  Both micelles had their highest fracture accumulation intensities at 24 h 
relative to other organs.  Liver to kidney accumulation was lower in the branched unimer, 
which correlates with the 24-h organ biodistribution data (Figure 3.7-24 h compared to 
Figure 3.6).  In both micelles throughout the experiment there was no apparent 
accumulation in the bowels, leading us to believe that most was excreted through 
urination.  Most importantly, there was no noticeable uptake in the healthy bone while the 
fractured bone had high accumulation. 
  Between the SPECT data and the organ biodistribution data there were a few 
discrepancies.  Primarily, the high ratio of renal accumulation to fracture accumulation in 
the organ biodistribution is not as pronounced in the SPECT data.  There are several 
explanations for this.  First, the kidneys contain proteins for the reabsorption of peptides 
from the urine [37,38].  It is plausible that peptide kidney transporters were saturated in 
the SPECT study due to a 100-fold increase in drug dose compared to the organ 
biodistribution.  Bone fracture targeting is not limited by a finite number of receptors as 
in the kidney; rather, it is limited by the surface area of the bone and may not have been 
similarly saturated.   
In addition, the organ biodistribution is measured in injected dose/gram and does 
not account for differences in tissue type or location of accumulation within an organ.  
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Bone is far more dense (1900 kg/m3) than soft tissue organs such as kidneys or liver 
(1030-1060 kg/m3) [39].  This difference in density dilutes the injected dose/gram 
measurements in bone compared to an organ such as a kidney.  While no hotspots are 
found in the kidney due to the accumulation being distributed throughout the entire 
kidney, the signal in fractured femur is further muted by the entire bone being weighed 
for the measurement rather than the fracture alone.  The combination of these factors 
better explains why in the SPECT study, accumulation per volume is much higher in the 
fracture compared to the kidney. 
 
3.4 Conclusions 
In this study we created two fracture-targeted micelles designed to increase the rate 
of healing in bone fractures.  These micelles are built on the concept that the micellar 
corona can function as both a moiety that gives amphiphilicity, as well as being a low-
toxicity targeting ligand.  Likewise, the 6BIO drug both functions as a pharmaceutical 
and gives stability to the micelle core.  The micelles also feature a hydrolyzable oxime 
ester bond to the drug that releases the drug unmodified over several days.    
In vivo, both the branched and linear micelle designs demonstrated excellent uptake 
in fractured bone versus healthy bone.  The branched unimer demonstrated both a higher 
ratio of fracture to kidney uptake and fracture to healthy bone accumulation over the 
linear unimer.  Future treatment studies will elucidate fracture-healing capabilities of 
these micelles and include histology of the kidneys and liver to assess any acute toxicities 
associated with the treatment. 
With an aging population and an increase in prescription bisphosphonates, 
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debilitating nonunion and delayed union bone fractures are inevitable.  The development 
of a bone anabolic agent delivery system has not caught up with the demand of an aging 
population.  The problem needs to be approached in a two-fold manner.  First, more basic 
research into understanding biochemical pathways in the fracture that might be employed 
in developing anabolic agents and understanding the bone microenvironment in order to 
develop better release mechanisms.  Second, applied research needs to be conducted 
controlling the deposition and release of anabolic agents.  This research answers some of 
the questions.  With additional studies, a nonsurgical treatment for delayed union and 




[1]  J.E. Shea, S.C. Miller, Skeletal function and structure: Implications for tissue-
targeted therapeutics, Adv. Drug Deliv. Rev. 57 (2005) 945–957. 	
[2]  A.S. Posner, F. Betts, Synthetic amorphous calcium phosphate and its relation to 
bone mineral structure, Acc. Chem. Res. 8 (1975) 273–281. 	
[3]  D. Wang, S.C. Miller, L.S. Shlyakhtenko, A.M. Portillo, X.-M. Liu, K. 
Papangkorn, P. Kopečková, Y. Lyubchenko, W.I. Higuchi, J. Kopeček, Osteotropic 
peptide that differentiates functional domains of the skeleton, Bioconjug. Chem. 18 
(2007) 1375–1378. 	
[4]  D. Lacey, E. Timms, H.L. Tan, M. Kelley, C. Dunstan, T. Burgess, R. Elliott, A. 
Colombero, G. Elliott, S. Scully, et al., Osteoprotegerin ligand is a cytokine that 
regulates osteoclast differentiation and activation, Cell. 93 (1998) 165–176. 	
[5]  H. Yasuda, N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S. Mochizuki, A. 
Tomoyasu, K. Yano, M. Goto, A. Murakami, E. Tsuda, T. Morinaga, K. Higashio, 
N. Udagawa, N. Takahashi, T. Suda, Osteoclast differentiation factor is a ligand for 
osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to 
TRANCE/RANKL, Proc. Natl. Acad. Sci. 95 (1998) 3597–3602. 	
[6]  H. Väänänen, H. Zhao, M. Mulari, J.M. Halleen, The cell biology of osteoclast 
function, J. Cell Sci. 113 (2000) 377–381. 	
		
113	
[7]  S. Harada, Control of osteoblast function and regulation of bone mass, Nature. 423 
(2003) 349–355. 	
[8]  R. Bartl, B. Frisch, C. Bartl, Osteoporosis: Diagnosis, prevention, therapy, 
Springer, 2009. 	
[9]  D.W. Dempster, Osteoporosis and the burden of osteoporosis-related fractures, Am 
J Manag Care. 17 (2011) S164–S169. 
[10]  G.B. Bishop, T.A. Einhorn, Current and future clinical applications of bone 
morphogenetic proteins in orthopaedic trauma surgery, Int. Orthop. 31 (2007) 721–
727. 	
[11]  K.L. Ong, M.L. Villarraga, E. Lau, L.Y. Carreon, S.M. Kurtz, S.D. Glassman, Off-
label use of bone morphogenetic proteins in the United States using administrative 
data, Spine. 35 (2010) 1794–1800. 	
[12]  P. Fournier, S. Boissier, S. Filleur, J. Guglielmi, F. Cabon, M. Colombel, P. 
Clézardin, Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated 
vascular regrowth in the ventral prostate in castrated rats, Cancer Res. 62 (2002) 
6538–6544. 	
[13]  E. Giraudo, M. Inoue, D. Hanahan, An amino-bisphosphonate targets MMP-9–
expressing macrophages and angiogenesis to impair cervical carcinogenesis, J. Clin. 
Invest. 114 (2004) 623–633. 	
[14]  T. Ziebart, A. Pabst, M.O. Klein, P. Kämmerer, L. Gauss, D. Brüllmann, B. Al-
Nawas, C. Walter, Bisphosphonates: restrictions for vasculogenesis and 
angiogenesis: inhibition of cell function of endothelial progenitor cells and mature 
endothelial cells in vitro, Clin. Oral Investig. 15 (2009) 105–111. 	
[15]  J. Ishizaki, Selective drug delivery to bone using acidic oligopeptides, J. Bone 
Miner. Metab. 27 (2009) 1–8. 	
[16]  S. Miller, H. Pan, D. Wang, B. Bowman, P. Kopečková, J. Kopeček, Feasibility of 
using a bone-targeted, macromolecular delivery system coupled with prostaglandin 
E1 to promote bone formation in aged, estrogen-deficient rats, Pharm. Res. 25 
(2008) 2889–2895. 	
[17]  S.A. Low, J. Yang, J. Kopeček, Bone-targeted acid-sensitive doxorubicin conjugate 
micelles as potential osteosarcoma therapeutics, Bioconjug. Chem. 25 (2014) 2012–
2020. 	
[18]  R. Baron, G. Rawadi, Targeting the Wnt/beta-catenin pathway to regulate bone 
formation in the adult skeleton, Endocrinology. 148 (2007) 2635–2643. 	
[19]  Y. Chen, H.C. Whetstone, A.C. Lin, P. Nadesan, Q. Wei, R. Poon, B.A. Alman, 
		
114	
Beta-catenin signaling plays a disparate role in different phases of fracture repair: 
implications for therapy to improve bone healing, PLoS Med. 4 (2007) 1216–1229. 	
[20]  G. Sisask, R. Marsell, A. Sundgren-Andersson, S. Larsson, O. Nilsson, Ö. 
Ljunggren, K.B. Jonsson, Rats treated with AZD2858, a GSK3 inhibitor, heal 
fractures rapidly without endochondral bone formation, Bone. 54 (2013) 126–132. 	
[21]  E. Piters, E. Boudin, W. Van Hul, Wnt signaling: A win for bone, Arch. Biochem. 
Biophys. 473 (2008) 112–116. 	
[22]  M. Prabaharan, J.J. Grailer, S. Pilla, D.A. Steeber, S. Gong, Amphiphilic multi-
arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond 
for tumor-targeted drug delivery, Biomaterials. 30 (2009) 5757–5766. 	
[23]  M. Hrubý, Č. Koňák, K. Ulbrich, Polymeric micellar pH-sensitive drug delivery 
system for doxorubicin, J. Controlled Release. 103 (2005) 137–148. 	
[24]  P. Polychronopoulos, P. Magiatis, A.-L. Skaltsounis, V. Myrianthopoulos, E. 
Mikros, A. Tarricone, A. Musacchio, S.M. Roe, L. Pearl, M. Leost, P. Greengard, L. 
Meijer, Structural basis for the synthesis of indirubins as potent and selective 
inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases, J. Med. 
Chem. 47 (2004) 935–946. 	
[25]  E.B. Corcoran, A.B. Williams, R.N. Hanson, A synthetic method for palladium-
catalyzed stannylation at the 5- and 6-benzo positions of indoles, Org. Lett. 14 
(2012) 4630–4633. 	
[26]  A.J. McCarroll, J.C. Walton, Photolytic and radical induced decompositions of O-
alkyl aldoxime ethers, J. Chem. Soc. Perkin Trans. 2. (2000) 1868–1875. 	
[27]  R.E. Marx, Y. Sawatari, M. Fortin, V. Broumand, Bisphosphonate-induced exposed 
bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, 
and treatment, J. Oral Maxillofac. Surg. 63 (2005) 1567–1575. 	
[28]  A. O Hoff, B.B. Toth, K. Altundag, M.M. Johnson, C.L. Warneke, M. Hu, A. 
Nooka, G. Sayegh, V. Guarneri, K. Desrouleaux, J. Cui, A. Adamus, R.F. Gagel, 
G.N. Hortobagyi, Frequency and risk factors associated with osteonecrosis of the 
jaw in cancer patients treated with intravenous bisphosphonates, J. Bone Miner. 
Res. 23 (2008) 826–836. 	
[29]  J.F. Madison, Tetracycline pigmentation of teeth., Arch. Dermatol. 88 (1963) 58–
59. 	
[30]  S.A. Low, J. Kopeček, Targeting polymer therapeutics to bone, Adv. Drug Deliv. 
Rev. 64 (2012) 1189–1204. 	
		
115	
[31]  T. Sekido, N. Sakura, Y. Higashi, K. Miya, Y. Nitta, M. Nomura, H. Sawanishi, K. 
Morito, Y. Masamune, S. Kasugai, K. Yokogawa, K. Miyamoto, Novel drug 
delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics 
and pharmacological potential, J. Drug Target. 9 (2001) 111–121. 
[32]  F. Yuan, L. Quan, L. Cui, S.R. Goldring, D. Wang, Development of 
macromolecular prodrug for rheumatoid arthritis, Adv. Drug Deliv. Rev. 64 (2012) 
1205–1219. 	
[33]  K. Ren, P.E. Purdue, L. Burton, L.-D. Quan, E.V. Fehringer, G.M. Thiele, S.R. 
Goldring, D. Wang, Early detection and treatment of wear particle-induced 
inflammation and bone loss in a mouse calvarial osteolysis model using HPMA 
copolymer conjugates, Mol. Pharm. 8 (2011) 1043–1051. 	
[34]  U. Krause, S. Harris, A. Green, J. Ylostalo, S. Zeitouni, N. Lee, C.A. Gregory, 
Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells 
for improved osteoinductive therapy, Proc. Natl. Acad. Sci. USA. 107 (2010) 4147–
4152. 	
[35]  O. Swenson, Biochemical changes in the fracture hematoma, J. Bone Joint Surg. 
Am. 28 (1946) 288–293. 	
[36]  A. Schindeler, M.M. McDonald, P. Bokko, D.G. Little, Bone remodeling during 
fracture repair: The cellular picture, Semin. Cell Dev. Biol. 19 (2008) 459–466. 	
[37]  Y. Kanai, M.A. Hediger, Primary structure and functional characterization of a 
high-affinity glutamate transporter, Nature. 360 (1992) 467–471. 	
[38]  M.E. Ganapathy, W. Huang, H. Wang, V. Ganapathy, F.H. Leibach, Valacyclovir: 
a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2, 
Biochem. Biophys. Res. Commun. 246 (1998) 470–475. 	
















Figure 3.1. Fracture-targeting micelles from amphiphilic unimer consisting of aspartic 
acid octapeptide, miniPEG spacer, hydrophobic tail based on 11-aminoundecanoic acid 
































Figure 3.3: Dynamic light scattering of the linear micelle BIO-A2-D8 and the branched 





Figure 3.4. Time dependent 6BIO release from the linear micelle BIO-A2-D8 and from 
the branched micelle BIO-A2-K-D4 in PBS at 25°C  
 
 

















































Figure 3.6. Organ biodistribution of free 6BIO, the linear micelle BIO-A2-D8, and the 











































































HEALING EFFICACY OF FRACTURE-TARGETED GSK3β-LOADED 




Delayed-union bone fractures are common repercussions of decreased bone mass 
associated with old age.  In youth and young adults, common medical practice is able to 
heal most fractures.  As people age, however, common fractures have difficulty healing 
and cause a significant decrease in quality of life and an increase in morbidity.  Advances 
in treatment of these fractures have yet to catch up with aging populations.  The only 
anabolic drugs that are used for treating bone fractures are bone morphogenic protein 2 
(BMP-2) and teriparatide.  BMP-2’s route of administration is a local application during 
surgery, limiting the breadth of its application.  Teriparatide (recombinant human 
parathyroid hormone [rPTH] fragment 1-34), on the other hand, is applied systemically 
but affects bone mass of the entire body rather than just the fracture site.  The use of both 
of these anabolic agents for treating fractures is off label.  This leaves a gap for other 
anabolic agents such as GSK3β inhibitors to fill a need and be used for fracture therapy.  
The primary rationale for the use of a GSK3β inhibitor is that elevated Wnt leads to 




deletion of various proteins in the Wnt pathway such as frizzled-related protein-1 [4], 
sclerostin (a Wnt antagonist), antisclerostin [5], and Lrp5 (a critical transmembrane 
protein in the Wnt signaling pathway) [6] significantly affects bone turnover and fracture 
healing.  Furthermore, significant upregulation of B-catenin was found during fracture 
healing (12-week old mice) [7] and is partially responsible for the bone anabolic effects 
of both BMP-2 [8] and PTH signaling (teriparatide) [9]. 
There is a concern, however, with the promiscuity of the Wnt signaling pathway 
and its association with cancer [10–18].  Wnt is a signaling pathway in many types of 
cells and is associated with oncogenes, prompting the concern in upregulating the 
pathway through the inhibition of GSK3β inhibition.  Targeting the drug to bone 
fractures can mitigate these theoretical side effects.  By targeting the drug to bone, the 
GSK3β inhibition is primarily limited to the bone, kidneys, and liver. The issue is then 
reduced to: what involvement does Wnt have with liver, kidney, and bone cancers?  
Although it is evident that Wnt plays a critical role in many of these cancers, any 
association with GSK3β inhibitors administered over the short time to heal a fracture is 
weak [19–24].  The rationale for pursuing this pathway, however, is robust.   
The high bone-affinity aspartic acid octapeptide provides a promising method for 
targeting a promiscuous yet potent drug such as the GSK3β inhibitor, 6-bromoindirubin-
3’-oxime (6BIO), to bone fractures, accelerating healing with very few side effects.  
Previously, we developed an aspartic acid octapeptide containing a fracture-targeted 
micellar system that increases 6BIO accumulation preferentially in the bone fracture over 
healthy bone.  This micelle featured aspartic acid octapeptide targeting ligands that 




The targeting ligand is linked by a flexible miniPEG linker to two aminoundecanoic acids 
for increased micellar stability and ends in a ‘clickable’ azide-containing synthetic amino 
acid (azidohomoalanine).  The drug, 6BIO, is covalently bound to an alkyne-containing 
linker by a hydrolyzable oxime ester bond.  The linker is then clicked to the rest of the 
unimer and assembles into a micelle when reconstituted in an aqueous medium.  A 
second branched micelle was also developed that demonstrated superior fracture 
accumulation over the linear micelle.  The second micelle is branched between the 
aminoundecanoic acid and the miniPEG by a lysine forming two branches, each with four 
aspartic acids on them.  This study seeks to employ the targeting potential of the micelle 
and the anabolic action of 6BIO to treat bone fractures in vivo. 
 
4.2 Experimental procedures 
4.2.1 Synthesis of unimers 
6BIO and all unimer synthesis was performed as described previously in Low et al. 
[26].  Briefly, micelle 6BIO was conjugated to 2,2-dimethylpent-4-ynoic acid using 
DCC/DIPEA coupling followed by purification with flash chromatography.  Unimers 
were constructed on chlorotrityl resin using solid phase peptide synthesis starting with 
Fmoc-Dab(N3)-OH.  Each amino acid was added through using HATU/DIPEA coupling 
and 20% piperidine in DMF for Fmoc deprotection.  Unimers were purified using reverse 
phase HPLC and coupled to the 6BIO linker using copper catalyzed azide-alkyne 






4.2.2 Mouse handling 
All animal experiments were performed in accordance with Purdue University’s 
IACUC approved protocols.  Forty (10 per group) 31-35g male CD4 Swiss Webster mice 
were purchased from Harlan laboratories.  Mice were able to move freely throughout the 
experiment.  At 3 weeks following fracture induction, mice were euthanized using a CO2 
overdose.  Both fractured and healthy femurs were excised and fixed in formalin solution 
along with the kidneys and liver.  Mice were excluded from the study upon migration of 
the fracture stabilization pin or an insufficient fracture where the fracture did not pass 
through the bone. 
 
4.2.3 Mouse bone fracture 
A stabalized femoral fracture was performed under aseptic conditions with 
isoflurane anesthesia.  Skin around the knee was shaved and cleaned with an alcohol pad 
first, then with Betadine solution.  The skin incision was made over the knee.  The patella 
was then dislocated and a small hole was made under the patella with a 25-guage needle. 
The needle was used to ream the intramedullary canal. A 22-guage locking nail produced 
by flattening both ends was then inserted. The incision site was sutured and the femur 
was then fractured using a three-point bending device.  Buprenorphine (0.05 – 0.1 mg/kg) 








4.2.4 Mouse dosing 
Mice were dosed intravenously by tail vein injection every 3 days, starting on the 
day of fracture induction.  Micelles were reconstituted in sterile PBS while 6BIO was 
reconstituted in 1% DMSO and PBS.  Dosages were calculated assuming 1% fracture 
accumulation with a 20 nM concentration being necessary to elicit accelerated bone 
growth for the 5 nM enzymatic IC50 of 6BIO.  Mice receiving drug dosages were 
administered 6.9 nmol/kg/dose in approximately 0.1 mL of PBS.  PBS control mice 
received 0.1 mL of PBS. 
 
4.2.5 µCT analysis 
Scanco µCT 40 was used to collect CT images and data of bone.  The bones were 
scanned while immersed in PBS to prevent dehydration.  Scanco µCT software was used 
to analyze the images for bone density, total volume (TV), relative bone volume 
(BV/TV), trabecular thickness (Tb.Th), and trabecular spacing (Tb.Sp).  Volumes of 
interest included the fracture callus, and both cortical and trabecular bone between the 
points on the cortical bone where the bone was fractured. 
 
4.2.6 Images 
Images collected from the µCT were studied using Image J software.  Average 
pixels of a 3-dimensional reconstruction of a 50-slices stack were used and represent 
approximately 0.3 mm of tissue in depth.  Minimum brightness threshold was adjusted to 





4.2.7 Statistical analysis 
Statistical analyses were calculated using Prism GraphPad software.  Data are 
presented in results as mean ± standard error of the mean (SEM).  An unpaired student’s 
t-test was used to determine statistical significance, with P values less than 0.05 being 
considered statistically significant. 
 
4.2.8 Slide preparation 
Tissues were fixed in PBS-buffered formalin solution for at least 24 h.  Following 
fixation, tissues were embedded in paraffin, sectioned, and floated on slide.  Slides were 
deparaffinized and rehydrated for staining. 
 
4.3 Results and discussion 
We have developed two micelles designed to improve fracture healing in long bone 
fractures.  Previous studies of the micelles demonstrated their specificity to bone 
fractures.  Here, we tested the healing efficacy and biocompatibility of the micelles.  The 
first of the micelles is composed of a linear unimer design [25,26].  The drug, 6BIO, was 
conjugated to 2,2-dimethyl-3-butynoic acid by DCC/DIPEA coupling.  The 6BIO plus 
linker was then conjugated by copper-catalyzed azide-alkyne Huisgen cycloaddition to a 
unimer built using solid phase peptide synthesis.  The unimer was assembled starting 
with azidohomoalanine followed by two aminoundecanoic acids (A2), miniPEG (8-
amino-3,6-dioxaoctanoic acid), eight aspartic acids (D8), and capped with acetic acid, 
yielding BIO-A2-D8 (Figure 4.1).  BIO-A2-D8 features a targeting ligand that, upon 




as the drug and the core of the micelle, increasing the micelle’s stability.  Micelles gain 
their stability from hydrophobic interactions, so adding additional aminoundecanoic acids 
will make the micelle more stable [25].  Addition of too many aminoundecanoic acids, 
however, causes the unimers to aggregate in nonmicellar structures [25,26].  To 
circumvent this, a branched head group unimer was designed that increases conicity of 
the unimer [25].  The basic assembly was analogous to the linear unimer; however, 
following the two aminoundecanoic acids (A2), a lysine (K) was added that had both 
primary amines unprotected, providing two branches.  From the lysine, miniPEG was 
added, followed by four aspartic acids per arm (D4), and was capped with acetic acid, 
yielding the branched unimer BIO-A2-K-D4.  BIO-A2-K-D4 contains a total of eight 
aspartic acids, like the linear BIO-A2-D8, but is capable of being further stabilized with 
several additional aminoundecanoic acids while retaining a micellar structure.   
6BIO provided a good candidate drug for a therapy study due to its hydrophobicity 
as well as its excellent suppression of GSK3β.  Wnt works by inducing mesenchymal 
stem cells to differentiate into pre-osteoblasts.  The continual activation of the pre-
osteoblasts by Wnt leads to differentiated, active osteoblasts [27–30].  This means that as 
long as Wnt is active in the general fracture area, osteoblasts will continually be produced 
and active.  This is evident in fracture healing, as Wnt expression peaks during days 3-5 
and decreases between 14 and 21 days postfracture [2].  Previous studies on GSK3β-
inhibitor treatment of fractures have been successful by extending and amplifying Wnt 
expression, starting treatment on the day of fracture and continuing dosing on a daily 
basis until the end of the experiment [3].  Similarly, in this experiment we elevate Wnt 




micellar system delivered drug over 3 days, reducing administration by tail vein on every 
third day possible.   
The study was designed to replicate aged fractures while minimizing variance.  In 
order to best simulate an aged fracture, mature CD4 Swiss Webster mice (31-35g) were 
used.  Potential variance was mitigated by using male mice.  Estrogen levels play a 
significant role in bone growth with large changes in estrogen levels and bone densities 
occurring at pregnancy, lactation, and menopause [31–34].  Although these variations of 
estrogen levels are often associated with long-term changes in bone densities, there is 
evidence that estrogen levels can have dramatic effects with acute variations in estrogen 
[35], potentially correlating with estrous cycles.  
 
4.3.1 µCT analysis 
Upon completion of the study, femurs were harvested and underwent µCT testing.   
Information about the bone density, fracture volume, and callus structure was analyzed 
and used in determining the efficacy of the treatment regimen.  Bone density is an 
important tool for assessing bone healing, giving information about cellular activity as 
well as changes in structural integrity.  Bone density was calculated from the mass of the 
hydroxyapatite (HAp) mineralized part of the fracture callus per unit of the total volume 
of the fracture callus.  The linear and branched micelles yielded 411.1±17.3 mg HAp/cm3 
and 409.7±13.8 mg HAp/cm3, respectively, and were significantly higher than the free 
6BIO and PBS control, which were 337.8±14.2 mg HAp/cm3 and 348.6±22.7 mg 
HAp/cm3, respectively (Figure 4.2).  This overall increase of bone density in the treated 




well as targeted accumulation in the bone.  Although previous studies demonstrated a 2-
fold increase in fracture accumulation of the branched micelle over the linear micelle, the 
resultant bone densities of the linear and branched micelle treatments were not 
significantly different from each other.  Also of note, the PBS control and free drug did 
not differ significantly, indicating that the dose chosen for the study was lower than the 
amount needed for free 6BIO to initiate bone anabolism. 
 The relative bone volume (BV/TV) is the mineralized volume of the total volume 
and is a similar measurement to bone density.  Completing the trend observed by the 
bone density, the micelles outperformed the controls significantly.  The BV/TV of the 
linear micelle BIO-A2-D8 was 0.409±0.019 and branched micelle BIO-A2-K-D4 was 
0.409±0.011, while the free 6BIO was 0.338±0.015 and PBS control was 0.332±0.021 
(Table 4.1). 
The differences in bone densities can be explained partly by measured differences 
in the bone architecture.  Trabecular thickness (Tb.Th) is a measurement of the thickness 
of all of the mineralized trabeculae.  Greater Tb.Th is indicative of a more robust 
osteoblast population [36,37].  The BIO-A2-D8 and BIO-A2-K-D4 values were 
0.175±0.011 mm and 0.170±0.007 mm, respectively, and again significantly higher than 
the free 6BIO and PBS control, which were 0.134±0.007 mm and 0.139±0.014 mm, 
respectively.   
The converse of Tb.Th, the trabecular spacing (Tb.Sp), is a deleterious attribute that 
measures the distances of noncalcified portions of bone between the calcified portions 
[36].   Little difference between the samples was observed.  The only significant 




PBS control (0.181±0.004 mm).  By comparing Tb.Th to Tb.Sp, it is evident that the 
greatest contribution to bone density is produced by the thickness of the trabeculae. 
In addition to the densities and microstructure of the callus, larger callus volumes 
are associated with improved mechanical properties [38].  The callus volume is 
calculated from the total volume (TV) occupied by both calcified bone and soft tissue.  
The BIO-A2-D8 and BIO-A2-K-D4 micelles had TVs of 60.8±3.4 mm3 and 66.9±6.8 
mm3, respectively, while the free 6BIO and PBS control were 48.2±5.8 mm3 and 
44.1±8.8 mm3, respectively.  The combination of a significantly larger callus volume and 
increased bone density are clinically important signs that the targeted micelles are 
working. 
During the fracture healing process the original cortical bone undergoes remodeling 
by degradation and replacement with new bone.  Under extreme GSK3β inhibition, 
remodeling favors osteoblasts and osteopetrosis may occur.  It is unclear whether GSK3β 
inhibition resulting in osteopetrosis is a result of systemic inhibition of osteoclasts and 
whether local GSK3β inhibition will inhibit local favorable catabolism [39].  Transverse 
µCT sections 0.3 µm thick revealed that in both the micelle groups, the original cortical 
bone has undergone a great deal of remodeling, indicating that dosages were either not 
high enough to suppress local osteoclast activity, or migration of osteoclasts into the 
fracture was sufficient to overcome local suppression (Figure 4.3).  Evidence of 
remodeling appears to be greater in the targeted micelles over the controls as the lines 
differentiating between the original cortical bone and the fracture callus are difficult to 





4.3.2 Histology of kidneys and liver 
Biodistribution studies showed high uptake in the lungs, liver and kidneys 
compared to the fracture in both micelle groups at 1 h.  By 4 h, both micelle groups 
demonstrated high uptake in the femurs.  The linear micelle still had high uptake in the 
liver and kidneys while the branched micelle had only high kidney uptake.  By 24 h both 
micelles demonstrated high signals in the femurs [26].  In this study, liver and kidneys 
were harvested. Liver sections showed no evident liver toxicity in morphology or cell 
concentrations (Figure 4.4b).  Some potential kidney toxicity was visible in the drug 
groups where slight glomerular constriction and cell accumulation was evident but data 




We demonstrated accelerated fracture healing by targeting the GSK3β inhibitor, 
6BIO, to the fracture site.  Both fracture bone mineral density and volume were 
significantly higher in the micelle treatment groups over both the free 6BIO and PBS 
controls.  Both micelles performed relatively well in the tissues analyzed for toxicity.  
Additional dose escalation studies are needed to determine whether the slight 
abnormalities in glomular health are caused by the micelle and whether fracture healing 
can be accelerated further.  Although differences between the micelles were minimal, the 
branched micelle is likely the best candidate for further studies due to its greater ability to 
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Figure 4.2.  Densities of fracture callus [mg HAp/cm3].  Both unimers are statistically 





Table 4.1. The comparison of bone morphometric analysis (f indicates that the unimer is 
statistically different than the free drug and p indicates that the unimer is statistically 










































Direct Model Linear Branched Free 6BIO PBS 
TV [mm3] 60.8±3.4f,p 66.9±6.8 f,p 48.2±5.8 44.1±8.8 
BV/TV 0.409±0.019 f,p 0.409±0.011 f,p 0.338±0.015 0.332±0.021 
Tb.Th[mm] 0.175±0.011 f,p 0.170±0.007 f,p 0.134±0.007 0.139±0.014 
















Figure 4.3. Average composite of fifty 6 µm (0.3 mm) slices a) linear, b) branched, c) 
free 6BIO, and d) PBS control.  Whites and yellows indicate higher densities than blues 
and purples.  The original bone from the femurs of the treatment groups are being 
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Figure 4.4. Histology sections of BIO-A2-D8, BIO-A2-K-D4, 6BIO, and PBS control of 










SUMMARY AND FUTURE PROSPECTS 
 
5.1 Summary 
Bone diseases are a major cause of decreased quality of life and increased morbidity 
among all age groups.  In children and adolescents, these include bone cancers, such as 
osteosarcoma, and several genetic diseases [1–10].  In the elderly and 
immunocompromised, diseases of the bone include osteomyelitis, multiple myeloma, low 
bone density and osteoporosis, metastasis of other cancers to the bone, and nonunion and 
delayed union fractures.  Though over a sixth of the U.S. population suffers from one or 
more of these diseases [11], research into possible treatments has been relatively 
undeveloped despite numerous possible treatment strategies [12–14]. 
A common thread among many of these diseases is that bone is either being 
degraded or grown.  At these sites of bone turnover, increased therapeutic accumulation 
can be achieved by using targeting ligands such as aspartic acid octapeptide [15–29].  We 
designed a micelle using aspartic acid octapeptide targeting that can be coupled with the 
appropriate drug and adapted to treat several disease states.  
The basic micelle construct focuses on the multifunctionality of each component to 
ensure simplicity of the final product.  The targeting ligand, aspartic acid octapeptide, 
functions as both a targeting moiety as well as the corona of the micelle.  In addition, the 
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drug payload is covalently bound to the micelle by a hydrolyzable linker and functions 
both as a therapeutic and stabilizing element to the micelle core.  Joining the targeting 
ligand and drug is a flexible hydrophilic linker conjugated to a hydrocarbon tail for 
increased stability (Figure 5.1). 
 
5.1.1 Micelles for treatment of osteosarcoma 
Our initial studies of this micellar construct were on doxorubicin with the intention that 
the hydrophobic drug core could be changed, depending on the application.  Loaded with 
doxorubicin, the stability was increased with the addition of more hydrophobic sections; 
however, increasing the hydrophobicity too much on the linear design began to cause 
nonmicellar aggregation.  Branching the aspartic acid head group increased the conicity 
of the micelle, avoiding the previously observed undesired aggregation.  Micelle size and 
shape of all constructs were confirmed using dynamic light scattering and cryogenic 
electron microscopy.   
 
5.1.1.1 In vitro analysis of the micelle gave promising results  
for future in vivo work 
All micelle structures bound quickly to hydroxyapatite as expected.  Drug release 
occurred over several days and was positively correlated with the stability of each 
micelle.  Critical to the micelle’s success in this and other applications, drug-loaded 
micelles demonstrated toxicity to osteosarcoma cells, while the micelle structure without 




5.1.2 Bone fracture targeted micelles 
With a biocompatible micelle construct, we adapted the micelles to target anabolic 
agents to bone fractures.  Two micelles were compared, varying only in that one was 
branched and the other linear.  The modified micelles featured a GSK3β inhibitor linked 
to the micelle by a hydrolyzable oxime ester bond.  The drug, 6-bromoindirubin-3’-oxime 
(or 6BIO) inhibits GSK3β and therefore increases Wnt signaling (Figure 5.2).  With Wnt 
signaling, active progenitor cells differentiate into osteoblasts and are activated.  The 
activated osteoblasts then increase bone growth dramatically, making this construct an 
ideal drug delivery system for repairing bone fractures [30,31].  
Initial studies were used to determine in vivo targeting of the micelles.  It was 
elucidated through a 24 h biodistribution study that the micelle accumulation was higher 
in fractures than in healthy bone.  We found by doing time course SPECT/CT imaging 
that targeted drug accumulation in the fractures was far higher than previously thought 
and that the free drug clears through the liver-bowel route while the micelles 
preferentially are cleared through the kidneys and excreted in urine.  The primary sites of 
off-target effects were the liver and kidneys, which were studied in greater detail in the 
treatment study.  The critical information gathered from both biodistribution studies was 
that the branched micelle outperformed the linear micelle in both fracture to kidney 
uptake as well as fracture to healthy bone uptake.  
Following the biodistribution studies, a drug efficacy study was performed.  
Fracture healing was measured in both the linear and branched micelle, free 6BIO, and 
PBS control groups.  Both micelles demonstrated increased bone mineral density and 
fracture callus volume over the control groups.  Histology of the liver showed no visible 
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toxicity, while the kidneys showed a small amount of glomerular constriction in both 
micelle groups.  
By applying the micelles to both osteosarcoma and bone fractures, we demonstrated 
the versatility of the designed micelles.  When comparing the micelles against each other, 
the branched structure appears to be superior.  The branched unimer not only 
demonstrated improved targeting abilities, but it is more versatile in its ability to be 
stabilized with the addition of hydrophobic regions.    
 
5.2 Future directions 
The greatest potential for this drug delivery system lies with its ability to target 
fractures.  With 300,000-620,000 delayed union and nonunion fractures a year in the U.S. 
alone, a fracture-targeted drug has a large market to drive development and is clinically 
relevant [33].  This fracture-targeted drug’s clinical success depends on 1) refining the 
drug selection, 2) developing a proper drug-targeting moiety linker, 3) finding the 
optimal stability, and 4) completing preclinical testing.  
 
5.2.1 Drug selection 
6BIO is an effective bone anabolic agent.  For clinical success, however, it is 
important to make sure other bone anabolics are not better.  A great deal of research has 
gone into studying bone anabolic agents including GSK3β inhibitors,[30,31,34,35] 
prostaglandins [36–38], statins [39–45], bone morphogenic proteins [46,47], TGFβ 
[48,49], and parathyroid hormone [50–53]. The selection of an anabolic agent becomes 
complicated as many of the anabolic agents increase concentrations of other anabolic 
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agents.  For example, the prostaglandin E series increases BMP2 production as well as 
bone turnover by upregulating RANKL [37,54,55], while statins increase BMP2 and 
prostaglandins [44,45]. Attempts have been made to compare the anabolic action of 
several drugs in several different scenarios [48,56–58], but an across-the-board 
comparison study of efficacy in treating bone fractures has yet to be done.   
A series of studies determining several anabolic agents' fracture-healing capabilities 
would be an important development in the field.  Initially, an in vitro study would be used 
to compare each anabolic agent and to determine an approximate baseline of 
mesenchymal stem cell activation and differentiation into osteoblast-like cells.  
Mesenchymal stem cells (MSCs) would be harvested from mice, plated, and grown until 
confluent in 6-well plates.  Each bone anabolic agent would then be added at serial 
dilutions and incubated for 8 days.  The media would be removed, and the cells would be 
incubated with osteogenic media for 15 days and stained with Alizarin red S for detecting 
calcium deposits [59].   
Following the preliminary in vitro study, an in vivo study would serve to solidify 
the results.   Each anabolic agent would be dissolved in a solvent such as N-methyl-2-
pyrrolidone (NMP) and added to a poly(D,L-lactide-co-glycolide) (PLGA matrix 
(Atrigel).  Commercially available 3-month-old mice would be used because they are 
fully-grown.  Following fracture induction and stabilization using an intramedullary 
locking nail, the anabolic agent/matrix would be injected at the site of the fracture and 
released over time.  The mice would be euthanized at 3 weeks, a time point at which we 
previously found demonstrable differences between treatment groups and controls.  The 
femurs would then be excised and bone growth measured by microCT [60].    
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5.2.2 Linker selection 
Proper linker selection is critical to clinical success.  A proper linker can reduce the 
frequency of dose administration by extending drug release over several days.  The rate is 
limited by the chance of the hydroxyapatite-adsorbed drug being encased by growing 
bone.  An ideal release mechanism would include a fracture-specific release mechanism, 
releasing at a rate that is ideal for the drug delivered, and completely released before bone 
turnover encapsulates the drug in new bone. 
   Several degradable linkers, including enzymatic, pH-sensitive, and reduction-
sensitive linkers should be considered.  Enzyme-sensitive linkers are released by 
endopeptidases found in bone.  Some target peptidases include cathepsin K [61,62], 
cathepsin B [63–65], and cathepsin L [66–68], where cathepsin K is the most specific to 
bone and has been studied in drug delivery to both bone cancers and osteoporosis [61,69].  
Two problems with using an endopeptidase-specific degradable linker exist.  First, if the 
drug reduces the number of osteoclasts in the area, then there will also be less cathepsin 
K to release the drug.  Second, if the linker is attached to a drug on the inside of the 
micelle, significant steric hindrance may reduce drug cleavage significantly. 
  Several linkers rely on an acidic or basic environment to be released.  Osteoclast 
lacunae have a pH around 4-4.5 [70,71].  At this pH, hydrazone and acetal linkers will 
release their conjugate drug.  In addition, both linkers can be modified to release drug 
faster or slower by adding electron-withdrawing groups or electron-donating groups near 
the release site, respectively [72].  Again, if the drug reduces the osteoclast number in the 
area, the reduced pH of the lacunae will not be available and release may be hindered.   
The majority of the fracture callus is at a neutral to basic pH (6.9-7.6) [73].  Oxime 
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esters, such as the one in our construct, release under neutral to basic conditions and, like 
the acid sensitive linkers, are tunable.  Unfortunately, this pH range is also the normal 
physiological pH and gives no specificity to the fracture site.  Thus, the specificity of 
release lies with the targeting ligand.  For a base-sensitive linker to work, the cleavage 
rate must be slowed in order to release minimal drug in circulation prior to target 
accumulation. 
Finally, glutathione is often released in the body in response to injury [74–76]. A 
reducible linker such as a tunable disulfide could be an effective way to deliver 
drug[72,77–79].  To the best of our knowledge, reducible bonds have yet to be examined 
in bone fractures.   
Selecting a proper drug linker depends on the elucidation of several unknowns 
about the fracture microenvironment.  A direct solution would be to study the rate of 
release in mouse femoral fractures.  Near-infrared dyes are capable of being imaged 
through tissue.  By targeting a near-infrared (NIR) dye to a bone fracture using aspartic 
acid octapeptide, a baseline accumulation and fluorescence could be established.  By 
using the concepts of Förster resonance energy transfer (FRET), the fluorescence of the 
targeted NIR dye could be quenched by transferring its excitation energy to a neighboring 
Black Hole quencher dye.  By targeting a NIR dye linked to a Black Hole quencher dye 
by one of the linkers listed above, the NIR dye would be quenched until it is gradually 
released by its respective stimuli (Figure 5.3) [80–82].  The release kinetics could be 
determined by measuring fluorescence at different time points and comparing the 
fluorescence to that of the control at the same time point.  Once the quencher dye release 
began to plateau, if the predicted amount targeted is higher than the measured amount 
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released, then one might conclude that the rate was too slow and that the complex must 
have been encapsulated in bone prior to release. 
 
5.2.3 Modification of micelle stability 
Once the optimized drug and linker for clinical application have been confirmed, 
establishing the stability of the micelle in circulation is necessary.  Previously we have 
demonstrated how to increase stability of micelles and that at injected concentrations the 
micelles are stable, but we have no in vivo data to determine whether the stability is 
sufficient to withstand the sheer forces and dilution experienced in the bloodstream, as 
well as the milieu of proteins and plasma. Micellar stability in vivo could be measured by 
encapsulating a NIR dye in the micelle.  The micelle would be injected and intravital 
confocal microscopy would be used to measure fluorescence in the bloodstream over 
time[83–86].  The imaging can be performed noninvasively by focusing a Nikon A1R 
CLSM system on the blood vessels in the mouse ear lobe.  The NIR dye-loaded micelle is 
then injected by tail vein injection.  Images from three focal plains are collected every ten 
seconds for the first 5 minutes and then every 30 seconds for the remainder of the 
experiment.  The imaging and experiment is stopped upon reaching background 
fluorescence, indicating that all of the intact micelles have exited the blood stream.  If the 
micelle prematurely destabilized, a sharp peak of fluorescence would be detected due to a 
dramatic reduction in self-quenching, followed by a quick decrease in fluorescence 
[83,87]. Premature destabilization would indicate that the micelle’s stability needs to be 
increased.  Sufficiently stable micelles cause a certain degree of self-quenching of the 
dye, producing a moderate fluorescence up to several hours after injection, and would be 
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stabile enough to continue with further studies[83].  Alternatively, tritiated cholesterol 
can also be entrapped in the micelle and injected into mice.  With a specific activity of 
1.48-2.22TBq/mmol and a lower detection limit of beta counters being lower than 1Bq 
per liter [88], entrapment of minimal amounts of tritiated cholesterol may have smaller 
effect on composition and structure than entrapment of detectable levels of a NIR dye.  
With the tritiated cholesterol technique mice would then be euthanized at several time 
points and radioactivity of the fracture could then be measured.  If the micelles 
prematurely destabilize, the tritiated cholesterol bone accumulation would be low.   
If the micelle stability is insufficient, the branched construct can be stabilized by 
addition of more aminoundecanoic acids [89,90], equilibrating the micelle in solution 
longer prior to injection [89], or using one of the studied degradable linkers to cross-link 
the unimers within the micelle.  
 
5.2.4 Preclinical evaluations 
Critical to the micelle’s success are preclinical evaluations, including a dose 
escalation study, a study identifying the types of fractures the micelle will repair, and 
studies demonstrating the drug’s efficacy in other animals. 
A dose escalation study will achieve several things for the development of the 
micelle.  A dose escalation study will establish the optimal regimen for accelerated 
fracture healing and demonstrate a dose-dependent response to the drug and unveil any 
toxicity.   
The proposed dose escalation study would be modeled after work performed in 
Chapters 3 & 4.  Starting with 10 mice per group (6.9 nmol/kg/dose, 0.69 µmol/kg/dose, 
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69 µmol/kg/dose, 6.9 mmol/kg/dose and PBS), mice would be dosed intravenously by tail 
vein injection every 3 days, starting on the day of fracture induction.   During the study, 
mice would be weighed and monitored to ensure the administered dose is not acutely 
toxic enough to cause weight loss.  At three weeks, mice would be sacrificed and organs 
harvested.  Due to results we obtained in the biodistribution studies (see chapter 4), the 
target organs and tissues that would be collected for analysis would be femurs, lungs, 
liver, kidneys, and blood.   Bone densities of femurs would be measured using microCT.  
Bone fracture densities are expected to increase as higher dosages are administered until 
a maximum effective dose is reached and the increased bone density from drug 
administration plateaus.   However, with some anabolic agents such as rostaglandins, 
overdosing may result in bone loss due to excess inflammation, and such a response 
would also be shown in a dose escalation study.   Following microCT measurements, 
harvested femurs, lungs, liver, and kidneys would be sectioned and H&E-stained for 
general pathological analysis.  Additional slides and stains could include tartrate-resistant 
acid phosphatase (TRAP) in order to identify suppression of osteoclasts, and dual 
calbindin D28k (CalD) and aquaporin-2 (AQP-2) staining of the kidneys to identify 
nephrotoxicity[91].  Finally, kidney toxicity could be measured using a urine ELISA of 
alpha glutathione S-transferase (alpha-GST), and liver toxicity could be measured using 
blood levels of transaminases (such as ALT and AST).  Ideally, the maximum effective 
dose would be reached prior to any significant toxicity.  If significant toxicity occurred at 
the maximum effective dose, then lower, less toxic doses would be used for additional 
studies. 
 In a clinical setting, large differences between groups of people and types of 
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fractures exist, making a dose expansion study important.  A drug that accelerates healing 
in a juvenile mouse model and translates to accelerated healing in youth would represent 
a new standard of care for bone fractures; however, youth already have excellent bone 
repair mechanisms and success for this drug construct is more likely found in difficult-to-
heal models.  Nonunion fractures are a type of fracture that is often repaired with surgery, 
but a nonsurgical approach to assist with bone repair would substantially decrease 
morbidity.  Mouse models representing delayed unions are well-established, and a bone 
anabolic may be able to accelerate healing in these as well [92–94].  However, a major 
issue that may affect targeting delayed-union fractures is low blood supply, so selection 
of this type of fracture should be carefully considered before investing too many 
resources to it.  Fractures in mature and aging adults take longer to heal than in juveniles.  
It is thought that the cytokine response duration remains the same among age groups, but 
in the elderly either fewer osteoblasts are in place to repair the bone, or the osteoblasts 
present are in a more senescent state [95].  By increasing the time period that the cytokine 
response is active with an anabolic agent, accelerated healing may be possible.  Aged 
models are established [48,96] and were used in our studies.  Taking aged models a step 
further, osteoporosis induced by ovariectomy, low calcium, or hind limb immobilization 
would likely result in the most dramatic increases in bone healing over the controls 
[97,98].  Similarly, a clinically relevant model would be a mouse pretreated with 
bisphosphonates, impeding its ability to heal fractures. 
Often, success in one animal does not translate to success in another animal.  If 
success is observed in other animal models, such as rat, canine [99–101], porcine 
[102,103], or rabbit [104–106], the likelihood that human success will also be observed 
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greatly increases.  Observing success in multiple animals is not only a requirement for the 
FDA, but it also increases industry interest.  Porcine models are ideal because they are 
nonrodent and they are more commonly used for surgery than dogs [107]. 
 
5.3 Conclusions 
The field of targeting anabolic agents to bone fractures is an exciting and largely 
untapped area.  We have developed a bone-targeted micelle designed for treatment of 
various bone maladies, the most promising of which is likely fracture targeting.  The 
development of this micelle system is still in its infancy; however, success in either 
osteosarcoma or bone fractures would improve the lives of many individuals.  
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Figure 5.2: The differentiation and activation of osteoblasts through the Wnt/β-catenin 
signaling pathway.  Green arrows indicate active Wnt signaling and red arrows indicate 





Figure 5.3: Black Hole quenching dyes are capable of reducing fluorescence of NIR dyes 
in close proximity.  By targeting a NIR dye coupled by a degradable linker to a Black 
Hole quenching dye, one could measure the degradation of the linker at the fracture site.  
Upon degradation of the linker to a Black Hole quencher dye, the NIR dye fluoresces, 











CHAPTER 2 SUPPORTING INFORMATION 
 
A.1 Fmoc-Hydrazine 
 The structure and purity of synthesized Fmoc-hydrazine were verified by 1H-NMR 
and analytical HPLC, as shown in Figures A.1 and A.2. 
 
Figure A.1: 1H-NMR spectrum of Fmoc-hydrazine (using DMSO-d6 as solvent on 





Figure A.2: HPLC elution profile of Fmoc-hydrazine using Agilent Technologies 1100 
series  (Zorbax C18 column 4.6×250 mm) with gradient method from 2 to 90% of Buffer 
B within 30 min and flow rate 1.0 mL/min (Buffer A: deionized water (DI H2O) with 




A2 Fmoc-aminoundecanoic acid 
 The synthesized Fmoc-aminoundecanoic acid was characterized with mass 
spectrum, 1H-NMR and HPLC analytical profiles (A.3, A.4, and A.5, respectively):  
 
 






Figure A.4: HPLC profile of Fmoc-aminoundecanoic acid (Fmoc-AUA) using Agilent 
Technologies 1100 series  (Zorbax C18 column 4.6×250 mm) with gradient method from 
2 to 90% of Buffer B within 30 min and flow rate 1.0 mL/min (Buffer A: deionized water 




Figure A.5: 1H-NMR spectrum of Fmoc-aminoundecanoic acid (DMSO-d6, recorded on 




A3 Characterization of unimers synthesized by solid phase  
peptide synthesis (SPPS) 
 Figures A.6-A.13 represent analytical HPLC and MALDI-ToF spectra of four 
unimers following solid phase peptide synthesis, cleavage, and preparative HPLC 
purification: 
 
   





























































































































































































































Figure A.10: Structure and MALDI-ToF spectrum of A1-D8. 
 
 






















































































































































































































A4 Characterization of DOX – unimer conjugates 
 Below are HPLC profiles (A.14-A.17) of the four unimers (described above) 
following conjugation to DOX via hydrazone bond and purification on a LH20 column: 
 
 
Figure A.14: Chemical structure and HPLC profile of DOX-A1-D8. 
 
 



















































































































Figure A.16: Chemical structure and HPLC profile of DOX-A2-K-D4. 
 
 























































































































































 CHAPTER 3 SUPPORTING INFORMATION 
 
B.1 Synthesis of 6′-bromoindirubin-3′-oxime  (BIO) 
 
Figure B.1: HPLC and mass spectrometry of purified 6BIO.  6BIO contains a bromine, 




Figure B.2: NMR of 6BIO in DMSO.  1H NMR (500 MHz, DMSO-d6) δ  11.74 (s, 1H), 
10.84 (s, 1H), 8.54 (d, J = 8.5 Hz, 1H), 8.21 (dd, J = 7.6, 1.0 Hz, 1H), 7.44 – 7.39 (m, 





B.2 Conjugation of 6BIO to 2,2-Dimethyl-3-butynoic acid 
 
Figure  B.3:  HPLC and mass spectrometry of the purified product of 6BIO and 2,2-







Figure  B.4:  NMR of the purified product of 6BIO and 2,2-dimethyl-3-butynoic acid in 
DMSO.  1H NMR (500 MHz, DMSO-d6) δ 11.62 (s, 1H), 11.00 (s, 1H), 9.06 (d, J = 8.5 
Hz, 1H), 8.28 – 8.05 (m, 1H), 7.53 (ddd, J = 8.3, 7.2, 1.2 Hz, 1H), 7.49 (dt, J = 8.0, 1.0 
Hz, 1H), 7.14 (td, J = 7.5, 1.2 Hz, 1H), 7.11 (dd, J = 8.5, 2.0 Hz, 1H), 7.03 (d, J = 1.9 Hz, 




B.3 Synthesis of unimers 
 








B.4 Final ‘clicked’ unimers BIO-A2-D8 and BIO-A2-K-D4 
 










B.5 Release kinetics 
BIO-A2-D8 0h BIO-A2-D8 1h 
  
BIO-A2-D8 2h BIO-A2-D8 4h 
  










BIO-A2-D8 24h BIO-A2-D8 48h 
  









BIO-A2-K-D4 0h BIO-A2-K-D4 1h 
  
BIO-A2-K-D4 2h BIO-A2-K-D4 4h 
  







Figure B.10: HPLC spectra of release kinetics for BIO-A2-K-D4. A small amount of free 
6BIO was present at time 0 and was used as a baseline for the other graphs.  
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BIO-A2-K-D4 24h BIO-A2-K-D4 48h 
  















B.6 Iodination preparation 
 




Figure B.13: Spectrum of o-alkylated stannylated 6BIO.  As is frequent the case with 







Figure B.14: Iodination of 6BIO.  The iodinated peak is at 7.7 minutes.  The primary 




Figure B.15: Iodination of BIO-A2-D8. The iodinated peak is at 5.3 minutes.  The 




Figure B.16: Iodination of BIO-A2-K-D4. The iodinated peak is at 5.1 minutes.  The 







APPENDIX C  
 
CHAPTER 4 SUPPORTING INFORMATION 
 
C.1 Bone morphometric analysis 
Table C.1: Bone morphometric analysis using the plate model (f indicates that the unimer 
is statistically different than the free drug and p indicates that the unimer is statistically 
different than the PBS control). 
Plate 
Model Linear Branched Free 6BIO PBS 
TV 60.5±3.4 f,p 66.7±6.8 f,p 48.1±5.8 43.9±8.8 
BV/TV 0.411±0.019 f,p 0.411±0.011 f,p 0.341±0.015 0.333±0.022 
Tb.N 5.24±0.12 f,p 5.66±0.11 5.73±0.20 5.78±0.18 
Tb.Th 0.0789±0.0043 f,p 0.0728±0.0021 f,p 0.0596±0.0021 0.0581±0.0047 
Tb.Sp 0.113±0.004 0.104±0.003 p 0.116±0.006 0.1157±0.0042 
BS 633.6±35.4 752.7±71.3 f,p 541.9±57.0 503.7±97.6 
BS/BV 25.9±1.5 f,p 27.6±0.8 f,p 33.8±1.2 35.3±2.7 
 
